## S1 Appendix - Biological age in UK Biobank: biomarker composition and prediction of mortality, coronary heart disease and hospital admissions

(Short title: Biological age biomarker composition and outcome prediction)

## Table of Contents

1. UK Biobank and study population ..... 3
UK Biobank. ..... 3
Study population ..... 3
Assessment dates and follow-up .....  3
Stratification by health status. ..... 3
2. Exposure and outcome preparation ..... 5
Biomarker data cleaning ..... 5
Phenotyping health outcomes. ..... 5
3. Statistical analyses ..... 7
A. Biomarker characteristics. ..... 7
B. Principal components of biomarkers ..... 7
C. Estimation of biological ages and mortality score ..... 7
D. Cross-validation of biological age estimation ..... 8
E. Biomarker importance in biological ages. ..... 9
F. Prediction of adverse health outcomes ..... 9
G. Explanatory power of biological ages. ..... 9
H. Calibration of biological ages ..... 9
4. Supplementary results ..... 11
Results of the biological age estimation and the prediction of health outcomes ..... 11
Cross-validation of biological age estimation ..... 11
Calibration of biological ages. ..... 11
Predictive power of biological ages ..... 11
Supplementary tables and figures ..... 12
Table 1: List of in-scope British National Formulary (BNF) Chapters and Sections related to chronic disease12
Table 2: Summary statistics for chronic disease medication count at baseline in the UK Biobank ..... 12
Table 3: Repeated measures Pearson correlation coefficients adjusted for baseline age for each of the 74 candidate biomarkers, by sex ..... 13
Table 4: Missingness and Pearson correlations of best measure and supplemented lung function baseline and repeated measurements ..... 14
Table 5: List of the 72 UK Biobank biomarkers selected for analysis, with percentage of missing data for each biomarker in the whole population ..... 15
Table 6: Constituent ICD-10 codes for the age-related hospital admissions definition, ranked by hazard ratioof baseline age in the UK Biobank17
$P$-values of hazard ratios for 10 years of age for each ICD-10 group were significant at the $10^{-3}$ level. ..... 17
Table 7: Number of events for each outcome in each prior health subpopulation, by sex ..... 18
Table 8: Pearson correlation coefficients of biomarkers with chronological age ranked by magnitude, in the Healthy subpopulation, by sex. ..... 18
Table 9: Model coefficients for (A) Klemera Doubal and (B) stepwise regression biological ages, in the Healthy subpopulation, by sex. ..... 20
Table 10: Importances of the 51 biomarker principal components in the Klemera Doubal ages for healthy men (left) and women (right) ..... 22
Table 11: Relative contribution (as a percentage of the total contribution of biological and chronological ages) of Klemera Doubal biological age and chronological age in explaining each health outcome, in (A) the main analysis (top) and (B) when using the reduced biomarker panel (bottom), for healthy men and women23
Table 12: Harrell's C-indices (with standard errors) for mortality score and biological ages, for each outcome and subpopulation in the main analysis (unadjusted). ..... 24
Table 13: Harrell's C-indices (with standard errors) for chronological age and biological ages, for eachoutcome and subpopulation in the (A) main analysis (top) and when $(B)$ using the reduced biomarker panel(bottom) (adjusted for environmental factors and health behaviours)25
Table 14: Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) checklist for this study ..... 27
Figure 1: Flowchart of selection of study population, before population stratification ..... 29
Figure 2: Flowchart of the classification process for UK Biobank medication names ..... 29
Figure 3: Biomarker-age trends for the 72 candidate biomarkers, healthy men vs healthy women ..... 30
Figure 4: Assessment of the need for stratification of healthy never vs healthy ex smokers: biomarker-age trends for the lung function biomarkers and systolic blood pressure, by sex ..... 33
Figure 5: Characterisation of 14 of the first 51 biomarker principal components ..... 34
Figure 6: 10-fold cross validation prediction errors (with standard error bars) for each subset of principalcomponents (to a maximum of 55) using (A) Klemera Doubal age (top) and (B) stepwise regression age(bottom), for healthy men (left) and women (right)39
Figure 7: Means and standard deviations of (A) Klemera Doubal (top) and (B) stepwise regression (bottom)biological ages by 2.5-year chronological age groups, for healthy men (left) and healthy women (right)40
Figure 8: Kaplan-Meier plots for (1) mortality from chronic disease, (2) age-related hospital admissions andstepwise regression biological ages, for healthy men (left) and healthy women (right)41

## 1. UK Biobank and study population

## UK Biobank

The UK Biobank is a large and richly phenotyped prospective study with over 500,000 participants in middle age when recruited in 2006-2010. ${ }^{1}$ The resource has collected and continues to collect extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, and longitudinal follow-up for a wide range of health-related outcomes. ${ }^{1}$ Details on the recruitment, biomarker measurement and data linkage procedures are available from the UK Biobank website. ${ }^{2}$ UK Biobank is an open access data resource for bona fide researchers who wish to use it to conduct health-related research for the benefit of the public, and access procedures are also detailed on the UK Biobank website. ${ }^{2}$

## Study population

This study included all participants in the UK Biobank data extract in April 2019. Information on sociodemographic characteristics, self-reported health behaviours, health ratings and medication were collected from touchscreen questionnaires. Linkage to Hospital Episode Statistics (HES) provided prior and prospective information on secondary care outcomes. Linkage to the Office for National Statistics (ONS) death registry provided date and cause of death. Over 100 biomarkers were measured via physical measurement devices, blood assays and urine assays. Sex, age (rounded down by month) and the date of assessment were available for all participants. Index of Multiple Deprivation 2010 score was grouped into quintiles within the UK Biobank population in each country.

Of the 502,536 participants in the UK Biobank, participants were excluded if they had no date of assessment or did not attend the verbal interview, had none of the blood count or plasma measurements, were younger than 40 or older than 70 years at baseline, or were missing their Index of Multiple Deprivation score. After these exclusions, there were 480,019 participants in the study population (Figure 1).

## Assessment dates and follow-up

Participants attended baseline assessment in 2006-2010 and a subset of $\approx 20,000$ participants attended a repeat assessment in 2012-2013. ${ }^{1}$ Participants were followed up for a median of 8.7 years to the death record censoring date of 31 January 2018 for English and Welsh participants or 30 November 2016 for Scottish participants. HES records were available for a median follow up period of 8.0 years, until 31 March 2017 for English participants, 31 October 2016 for Scottish participants, or 29 February 2016 for Welsh participants.

## Stratification by health status

A composite measure of prior health for stratification into 4 subpopulations was derived from self-reported characteristics at baseline interview and HES records, according to these definitions:

1. Healthy: No self-reported chronic disease medications, good self-reported health, steady/brisk walk speed,

0-2 HES episodes prior to recruitment, never/ex smoker, no prior disease or hip/wrist fracture
2. Some medications: 1-2 self-reported chronic disease medications, 0-2 HES episodes, no prior disease or hip/wrist fracture
3. Slightly unhealthy: Participants who do not fall into other categories
4. Poor health: Prior disease or hip/wrist fracture

Diseases in scope are age-related chronic diseases recorded in HES: Cardiac arrhythmia, chronic kidney disease, diabetes mellitus, heart failure, ischaemic heart disease, peripheral arterial disease, arthritis, rheumatoid arthritis, osteoporosis, gout, dementia, stroke/transient ischaemic attack, chronic obstructive pulmonary disease, connective tissue disease, liver disease and malignant cancers.

Self-reported medications were classified as chronic disease-related using a data-driven and text-mining approach applied to the 1366 medication names reported in the UK Biobank at April 2017. These medication names were mapped to British National Formulary (BNF) Chapters, Sections and Paragraphs that were defined by BNF as at December 2017. ${ }^{3}$ A clinician reviewed the classification of the 167 BNF Sections matched to the reported medication names. This medication classification process is summarised in Figure 2 and the 50 BNF Sections that were classified as chronic disease-related in this study are listed in Table 1.

A simple count of chronic disease medication types was done for each participant in the study, based on selfreported medication use at baseline. Participant responses were classified by a trained nurse during the verbal interview stage of the baseline assessment. This method of counting medication types was based on a procedure for counting BNF Paragraphs of reported medications, which was found to be predictive of mortality. ${ }^{4}$ No medication use was reported by $51.6 \%$ of participants, while the remaining $48.4 \%$ reported 787 chronic diseaserelated medications in the relevant BNF Sections identified earlier (Tables 1 and 2). The mean number of medications per participant for those reporting medication use was 1.72.

The phenotyping of non-cancer prior disease was based on a list of diseases and their respective ICD-10 codes derived from linked primary and secondary care records in England. ${ }^{5}$ Prior cancer was defined as malignant cancers (excluding in-situ neoplasms, benign neoplasms and non-melanoma skin cancers). ${ }^{6}$ Age-related chronic diseases were selected for use in this study were based on the following criteria: (1) commonly classified as a chronic rather than acute disease, (2) clear increasing trend in incidence with chronological age, and (3) not defined solely by levels of any biomarker in the candidate biomarker list.

Prior hip and wrist fractures were identified in participants using the ICD-10 codes S72 and S62 respectively.

## 2. Exposure and outcome preparation

## Biomarker data cleaning

As at April 2019, 110 physical and biochemical biomarkers were available in UK Biobank. Biomarkers were excluded from the panel for this study if they were measured in $<70 \%$ of the whole population, if they were not measured on a continuous scale, or if they measured the same biological trait (e.g. standardly-measured but not impedance device-measured weight was selected), leaving 74 biomarkers (Table 3).
'Best' measures for the included lung function biomarkers, forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), were defined by UK Biobank ${ }^{2}$ and available for $72 \%$ of men and $70 \%$ of women in this study. Up to 3 raw readings for each biomarker were also available. Both lung function biomarkers had the highest proportions of data missing within the biomarker panel, if only best measures were considered (Table 4). The raw readings provided two types of lower-quality measurements: (1) Remainder with 'accept' flags, created by taking the non-missing means of up to 3 readings flagged as 'accept' (available in an additional $4 \%$ of men and $4 \%$ of women); and subsequently (2) all remaining readings, created by taking the non-missing means of up to 3 available readings (measured in an additional $14 \%$ of men and $18 \%$ of women). Best measure, type (1) and type (2) baseline measurements were moderately or highly correlated with the type (1) repeated measures (Pearson correlation coefficients $>0.585$ ). Therefore, it is likely that these lower quality readings are more highly correlated with usual values than any general imputed value would be. The best measures were thus supplemented with these two types of measurements, reducing the missingness in the hybrid FEV1 and FVC measures to $10 \%$ and $8 \%$ for men and women respectively. (The use of additional readings has also been advocated by others. ${ }^{7}$ )

FEV1 and FVC, along with hand grip strength, were each divided by standing height. ${ }^{8}$ This was done to ensure that measurements for these derived biomarkers were not strongly determined by body size.

A further 2 biomarkers, oestradiol and nucleic red blood cell count, were excluded due to poor reproducibility, leaving 72 biomarkers (Table 5). In this study, biomarker measurement quality threshold was set at an intraindividual Pearson correlation coefficient adjusted by baseline age of more than 0.1 , in the repeat assessment subset of 9447 men and 9888 women (Table 3). These 72 biomarkers were categorised by body system group, based partially on the biomarker categorisation used by a review of biological age studies. ${ }^{9}$

Biomarker measurements were cleaned by this procedure:

1. Urinary and blood plasma biomarkers, flagged as below or above the assay reportable range ${ }^{10}$ were replaced with the respective limit of the range.
2. All biomarkers, values were standardised by subtracting their overall mean and dividing by their standard deviation. Body size biomarkers exhibited sex differences, therefore they were standardised separately within each sex.
3. Standardised values outside $\pm 4$ were treated as outliers, set to missing, and were subsequently imputed in step 4.
4. Imputation was carried out by replacing all missing values with the overall medians within 5-year baseline age, similar to a procedure based on imputing overall means. ${ }^{11}$ This was preferred to assigning a non-central biomarker value through multiple imputation ${ }^{12}$ and complete case analysis. ${ }^{13-16}$ Relative to chronological age, multiple imputation would skew individuals' biological ages in the direction that is indicated by the available biomarkers for each individual, and the degree of statistical inference applied to the missing biomarkers within the imputation procedure and the resulting uncertainty in biological age estimation are not communicated through their biological age. The use of complete cases based on biomarker measurements introduces bias into the estimation of biological ages that is difficult to quantify.

## Phenotyping health outcomes

Three adverse health outcomes were investigated in this study: (1) Mortality due to chronic disease; (2) incidence of a coronary heart disease-related event; and (3) first admission to hospital for an age-related reason. These outcomes were phenotyped from death registry and HES records, based on code lists and procedures published by previous studies. ${ }^{11,13,14,17}$

1. Mortality due to chronic disease:

Mortality is the most objective and most accurately recorded outcome available in UK Biobank. Based on ICD-10 coded causes of death, accidental deaths ${ }^{13,14}$ and non-chronic disease deaths ${ }^{11}$ were excluded, following previous studies' procedures. These deaths would not be much related to ageing processes and their high prevalence at younger ages might mask ageing-related mortality effects. The exclusions were specified by ICD-10 Chapter: certain infectious and parasitic diseases (A00-B99), pregnancy, childbirth and the puerperium (O00-O99), congenital malformations, deformations and chromosomal abnormalities (Q00Q99), injury, poisoning and certain other consequences of external causes (S00-T98) and external causes of morbidity and mortality (V01-Y98).
2. Incidence of a coronary heart disease-related event:

The incidence of a coronary heart disease (CHD) is commonly used as an adverse endpoint in clinical trials and observational studies of disease epidemiology. In this study, a CHD event was defined as a HES diagnosis or a death registry-recorded death, where the diagnosis or cause of death was coded as any of the following ICD-10 codes: I21, I251, I255, I259, I214, I219, I249.
3. First admission to hospital for an age-related reason:

Hospital admissions for age-related reasons may be symptoms of biological frailty and were identified through a frailty risk score for secondary care records. ${ }^{17}$ Frailty is a strong predictor for multimorbidity and mortality in the UK Biobank ${ }^{18}$ and adverse health outcomes in many other populations. ${ }^{19}$ It precedes mortality, and may be a general indicator of ageing earlier in life. However, not all components of frailty are age-related or are recorded in clinical care. Since the operational definitions of frailty (clinicianassessed frailty, variations of the frailty phenotype and frailty indices) differ, and further research is required to assess the ability of health record-based frailty indices to detect biological frailty, ${ }^{20}$ for the avoidance of doubt the term 'hospital admissions' was used instead.

The age-related hospital admisssion outcome in this study was constructed from the candidate ICD-10 codelist in the study of hospital frailty risk score for HES inpatients: ${ }^{17}$
a. Incident cases in the UK Biobank at April 2017 were identified for each of 75 candidate frailty subtypes, defined as standalone 3-digit ICD10 codes in HES diagnosis records with >500 incident cases, otherwise grouped ICD-10 codes within the same ICD-10 block (Table 6).
b. Hazard ratios per 10 years of baseline chronological age were then estimated for each candidate subtype as the outcome, with Cox models adjusted for smoking status, alcohol intake frequency and Townsend deprivation quintile.
c. Subtypes were included in the definition if this hazard ratio exceeded the threshold of 1.2.

The number of events for each outcome was summarised by prior health subpopulation and sex in Table 7.

## 3. Statistical analyses

## A. Biomarker characteristics

Biomarker-age trends were assessed for linearity and for homogeneity between sexes and across prior health subpopulations. To estimate biomarker-age trends, linear regression was used to obtain least-square means and standard errors of standardised biomarker values by 2.5 -year chronological age groups, separately by sex, adjusted for Index of Multiple Deprivation 2010 quintile, smoking status, alcohol consumption band and assessment centre. Trends for each biomarker were displayed on a common standardised scale for comparability (with original units included as a second scale), and visually assessed for linearity across age groups (Figure 3). These trends were assessed for linearity, as subsequent statistical methods assume linearity of biomarkerbiomarker or biomarker-age relationships.

To assess whether further stratification of the healthy subpopulation by smoker status was required, a sensitivity analysis of biomarker-age trends for healthy never vs ex smokers was carried out. All biomarkers were assessed, with a focus on lung function as it appeared to have the strongest linear relationship with chronological age, and is adversely affected by smoking. ${ }^{21}$ Figure 4 displays the trends for lung function biomarkers, which display the largest disparities by smoking status, and systolic blood pressure. The trends for the two lung function biomarkers were linear for each smoking status with a slight convergence at older ages, and the trends for the remaining biomarkers appeared to be similar regardless of smoker status. Therefore further stratification was not essential.

Pearson correlations, which assume linearity, were calculated for each biomarker and chronological age. The correlation coefficients for the healthy subpopulation are ranked by magnitude in S1 Table 8. Many previous studies used biomarker-age correlations to pre-select biomarkers for inclusion into biological ages. ${ }^{13-15,22,23}$ Preselection was not carried out in this study for two reasons: (1) to avoid selecting biomarkers that are potentially highly correlated with each other (due to their high correlation with chronological age), and (2) to allow methods for estimating biological age to complete their own selection process.

## B. Principal components of biomarkers

Principal Component Analysis (PCA) was used to summarise the biomarkers (dimensions) into linearly independent principal components, which are linear combinations or composites of the original biomarkers. ${ }^{24}$ PCA was run on the full set of biomarkers after imputing missing values for the whole population. The resulting biomarker principal components were ranked by their eigenvalues, representing the degree of variation in biomarker values that each principal component describes. Ranking principal components by their eigenvalues facilitated the selection of a smaller number of biomarker principal components that still represented the majority of variation biomarker values. The selection of biomarker principal components involved cross validation of the models for estimating biological age (S1 Appendix 3D).
To aid clinical interpretation, varimax rotation ${ }^{25}$ (which seeks to increase the contribution of biomarkers strongly loaded onto a principal component and decreases the contribution of those less strongly loaded) was applied after PCA. The rotated principal components were individually characterised based on the relative contributions of their constituent biomarkers, measured via rotated factor loadings (S1 Figure 5). The rotated factor loadings and the eigenvalues of the principal components were similar when run on the healthy subpopulation and the whole population (data not shown), thus only the results for the whole population were used in all subsequent analyses, for consistency in interpretation.

## C. Estimation of biological ages and mortality score

Previous studies ${ }^{13,25,26}$ that compared several estimation methods applied to clinical biomarkers reported that Klemera Doubal biological ages ${ }^{27}$ appeared to have the highest predictive power for health outcomes, followed by multiple linear regression (MLR), then PCA. A recent review of biological age estimation methods ${ }^{9}$ compared statistical properties and limitations of these three methods, and it listed more limitations in the MLR and PCA methods than in the Klemera Doubal method (KDM).

This study investigated the three main estimation methods, which were all based on linear regressions of chronological age with candidate biomarkers. Modifications were made, including the integration of the PCA method (described in the previous section) into both the $M L R^{25,28}$ and KDM, ${ }^{25}$ to improve the statistical properties of these methods.

## Method 1: Klemera Doubal Method (KDM) ${ }^{27}-$

This method assumes that its constituent biomarkers are uncorrelated and is based on two principles: (1) biological age summarises the differences between individuals' actual biomarker levels $x_{j}$, where $j=1, \ldots$, $m$ for $m$ candidate biomarkers, and characteristic biomarker levels for their chronological age; (2) biomarkers with stronger linear relationships to chronological age contribute more to biological age. ${ }^{27}$ The KDM biological age was estimated by linearly regressing each biomarker $x_{j}$ against chronological age, then taking the weighted sum of all the regression results, with the following form:

$$
\text { Biological age } \propto \sum_{j=1}^{\mathrm{m}}\left(\frac{k_{j}}{s_{j}^{2}}\right)\left(x_{j}-q_{j}\right)
$$

where $q_{j}=$ intercept, $k_{j}=$ coefficient and $s_{j}=$ standard error from the $\mathrm{j}^{\text {th }}$ chronological age-biomarker regression

Klemera and Doubal proposed a second version of biological age, which some studies found controversial, ${ }^{16,25}$ as it included chronological age as a biomarker. In order to assess biological ages both in isolation and jointly with chronological age, only the version of KDM age without chronological age as a biomarker was used.

Since this method does not involve biomarker selection and assumes that its constituent biomarkers are uncorrelated, this method was applied with and without prior PCA on candidate biomarkers. ${ }^{25}$ The former approach reduces interdependence between its constituents, while the latter approach was common practice. ${ }^{9,13,16,25,26}$

Method 2: Stepwise MLR -
This method represents biological age by the linear combination of biomarkers that explains the most variation in chronological age. This biological age is thus not statistically independent of chronological age, limiting its scope for prediction of health outcomes.

The standard MLR method, where biological age is the predicted value of chronological age regressed on all candidate biomarkers, ${ }^{9,13}$ was extended with a stepwise procedure that iteratively selected biomarkers that most explained chronological age, in the presence of other selected biomarkers. Stepwise regression was chosen over other variable selection or shrinkage methods, as multiple testing could be accounted for easily, through the specification of modified p-value thresholds. The Bonferroni-corrected p-value at the 0.05 level ( $0.05 /$ number of variables) was used as the stepwise selection criteria, to adjust for multiple testing and reduce correlation between selected biomarkers. This method was also applied with and without prior PCA on candidate biomarkers, for comparison with results from Method 1.

Benchmark for comparison: Estimation of mortality score -
Previous studies derived a mortality-based score ${ }^{29}$ and biological age ${ }^{30}$ for cause-specific mortality and comorbidity prediction, using penalised Cox proportional hazards models for variable selection. For consistency with the estimation of biological ages in this study, a benchmark mortality score was derived using the same biomarker panel, with a Bonferroni-corrected stepwise Cox model. The predictive power of the mortality score and the biological ages for CHD events and age-related hospital admissions were compared using C-indices from unadjusted Cox models stratified by sex and subpopulation (S1 Appendix $3 F)$.

Biological ages were estimated separately by sex, due to differences in biomarker-age trends by sex (S1 Figure 3). Additionally, mortality from chronic disease, prior and incident CHD and age-related hospital admissions were different between sexes (S1 Table 7).

## D. Cross-validation of biological age estimation

Cross-validation was carried out to check the stability of estimated biological ages and to identify the optimal number of biomarker principal components to include in the models. The initial criterion for the latter was the search for an elbow point in a plot of prediction errors for biological age estimation models run with an increasing number of principal components, ordered by decreasing eigenvalue, where beyond the elbow point there were diminishing changes in prediction error by increasing the number of principal components included in the model. If no clear elbow points were apparent, a second criterion of an eigenvalue threshold of $>0.33(1 / 3$ of the average variation in biomarker measurements described by a single biomarker in the UK Biobank) was
imposed, to avoid the inclusion of principal components that captured little biomarker variation in the population.

## E. Biomarker importance in biological ages

The relative importance of each biomarker was calculated as the proportion of variance in the biological ages explained by each constituent biomarker in the presence of the other constituent biomarkers ( $\mathrm{R}^{2}$ ). For both biological ages, it was derived using the Fabbris/Genizi/Johnson method ${ }^{31}$ implemented in the R package 'relaimpo,,${ }^{32}$ as recommended by a review of relative importance estimation methods in situations where there are large numbers of variables. ${ }^{33}$

## F. Prediction of adverse health outcomes

For each of the 3 outcomes defined in S1 Appendix 2, Cox proportional hazards models were run on the same subpopulations as those used in the biological age estimation, but excluding participants with prior events. They were stratified by sex and adjusted for Index of Multiple Deprivation 2010 quintile, smoking status, alcohol consumption, assessment centre, and age combinations (all variables were categorical except ages). Age combinations used were: (1) chronological age, (2) biological age, and (3) both chronological and biological age. Combination (3) was not used for stepwise regression ages, as stepwise regression ages cannot be combined with chronological age in a prediction model due to double counting.

Predictive power was assessed using Harrell's C-index, a measure for survival models equivalent to area under the receiver operating characteristic curve, both separately for the healthy and poor health subpopulations and for the whole population. The C-index and its standard errors were calculated using Kendall's tau. ${ }^{34}$

## G. Explanatory power of biological ages

To investigate the relationship between biological and chronological ages without reference to a specific health outcome, the proportion of variation in chronological age explained by each biological age was estimated in terms of $\mathrm{R}^{2}$ from univariate linear regressions. The proportion of the chronological age effect on mortality, CHD and hospital admission risk that was explained by each biological age was also estimated. The proportion of the biological age effect for each outcome explained by chronological age was also estimated in a similar way. This was done by comparing the log partial likelihoods of pairs of nested models, an extension of likelihood ratio tests:

$$
\begin{aligned}
& \text { Proportion of CA explained by } \mathrm{BA}=\frac{\left(l_{C A}-l_{\text {base }}\right)-\left(l_{B A+C A}-l_{C A}\right)}{\left(l_{C A}-l_{\text {base }}\right)} \\
& \text { Proportion of BA explained by } \mathrm{CA}=\frac{\left(l_{B A}-l_{\text {base }}\right)-\left(l_{B A+C A}-l_{B A}\right)}{\left(l_{B A}-l_{\text {base }}\right)}
\end{aligned}
$$

where $l_{m}$ : log-likelihood of model $m$, base: adjusted model without chronological or biological age, $C A$ : adjusted model with chronological age only, $B A$ : adjusted model with biological age only and $B A+C A$ : adjusted model with both biological and chronological age

Ratios were taken of these proportions to derive the relative contributions of biological age and chronological age to the combined age effect in predicting these health outcomes. The log-likelihood proportions above are equivalent to comparisons of the Nagelkerke pseudo- $\mathrm{R}^{2}{ }^{35}$ of the same pairs of models, which are approximations of $R^{2}$ for Cox models. Since biomarker importances are expressed in terms of $R^{2}$, biomarker importances and the relative explanatory power of chronological and biological ages can be jointly assessed in terms of $\mathrm{R}^{2}$ or its approximations.

## H. Assessing calibration of biological ages

To assess the calibration of biological ages with chronological age, the means and standard deviations for stepwise regression and KDM ages were plotted against chronological age, for each 2.5-year chronological age band in the age range of 40-70. A perfectly calibrated biological age would have mean biological age equal to mean chronological age in each age band. For biological ages that are not well calibrated, further transformations in order to recalibrate stepwise regression age to chronological age have been proposed ${ }^{6}$ but are only necessary at implementation stage.

To assess the risk calibration of biological ages, participants were stratified into 3 predicted risk groups based on the difference between their biological age (BA) and chronological age (CA): ${ }^{16}$ (1) BA - CA < -5 years (biologically younger), (2) $|\mathrm{BA}-\mathrm{CA}|<5$ years, and (3) BA - CA > 5 years (biologically older). For each biological age, sex and health outcome, Kaplan-Meier survival curves stratified by predicted risk group were plotted and assessed for overlap.

All statistical analyses were run in R version 3.3.3.

## 4. Supplementary results

## Results of the biological age estimation and the prediction of health outcomes

The model coefficients for the KDM and stepwise regression biological ages for the health subpopulation are tabulated in S1 Table 9. Further results for the KDM and stepwise regression biological ages and their prediction of health outcomes are listed in S1 Tables 10-13. The reporting of these results and other aspects of this study are summarised in the Guidelines for Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) ${ }^{36}$ checklist for this study (S1 Table 14).

## Cross-validation of biological age estimation

For the KDM and stepwise regression ages, prediction errors (mean square errors) were plotted against the numbers of principal components included in the models (S1 Figure 6). There were no clear elbow points in any subpopulation for either biological age. Hence the optimal number of principal components was determined to be 51 , based on the eigenvalue threshold of $>0.33$ per principal component.

## Calibration of biological ages

For a biological age to be communicated in terms of an age, it had to be calibrated to be similar to chronological age on average in the population. In each sex in the healthy subpopulation, the KDM age was well-calibrated with chronological age, but the stepwise regression age was too high at younger chronological ages and too low at older chronological ages (S1 Figure 7). Further rescaling to calibrate stepwise regression age to chronological age is not relevant for assessing its constituents and its relative predictive power, but is important for implementation in a clinical setting.

In order to communicate additional health information to chronological age, the difference between individuals' biological and chronological age had to be risk calibrated to demonstrate worse prognosis (if biological age was greater than chronological age) and vice versa, for each health outcome. For healthy men, there were slight differences in mortality, CHD and hospital admissions after 3-8 years from baseline, between the predicted risk groups based on the KDM age. These differences were smaller or undetectable for women. For the stepwise regression biological age, the predicted risk groups clearly differentiated risk of each health outcome after 4 years from baseline, but in the reverse direction (S1 Figure 8).

## Predictive power of biological ages

In unadjusted models for predicting health outcomes, both KDM and stepwise regression biological ages were more predictive of CHD events and hospital admissions than the mortality score in the healthy subpopulation (respective improvements in C-indices for CHD: 0.135 and 0.144 in men, 0.109 and 0.103 in women; for hospital admissions: 0.111 and 0.112 in men, 0.068 and 0.073 in women; S1 Table 12). The mortality score performed only slightly better than chance (equivalent to a C-index of 0.5 ). Both biological ages were slightly worse at predicting mortality due to chronic disease compared to the mortality score in the same subpopulation (respective improvements in C-indices: -0.015 and -0.012 in men, -0.013 and -0.018 in women). Based on Cindices from the adjusted prediction models (S1 Table 13), both KDM and stepwise regression biological ages were similarly predictive of CHD and less predictive of mortality and hospital admissions than chronological age in the healthy subpopulation, but had similar predictive power to the biological ages in the whole population.

The combination of chronological age and KDM age was the most predictive of mortality (S1 Table 13). Supplementing chronological age with KDM age did not increase C-indices in the healthy subpopulation ( 0.007 in men, 0.002 in women) but increased C-indices in the whole population ( 0.031 in men, 0.014 in women). Predictive power was significantly higher for mortality than for hospital admissions in the healthy subpopulation (C-indices: 0.731 [Standard error (SE): 0.0081] vs 0.662 [0.0029] in men, 0.690 [0.0092] vs 0.634 [0.0028] in women), and for men compared to women. Predictive power was significantly higher for mortality than for CHD in healthy men ( 0.731 [0.0081] vs 0.689 [0.0066]) but not women ( 0.690 [0.0092] vs 0.743 [0.0111]). Stepwise regression age cannot be combined with chronological age in a prediction model, because it was directly constructed by regressing its constituent biomarkers against chronological age.

## Supplementary tables and figures

Table 1: List of in-scope British National Formulary (BNF) Chapters and Sections related to chronic disease

| BNF Chapter | BNF Section |
| :---: | :---: |
| Cardiovascular System | Anti-Arrhythmic Drugs |
|  | Anticoagulants And Protamine |
|  | Antifibrinolytic Drugs \& Haemostatics |
|  | Antiplatelet Drugs |
|  | Beta-Adrenoceptor Blocking Drugs |
|  | Diuretics |
|  | Hypertension and Heart Failure |
|  | Lipid-Regulating Drugs |
|  | Local Sclerosants |
|  | Nit,Calc Block \& Other Antianginal Drugs |
|  | Positive Inotropic Drugs |
|  | Sympathomimetics |
| Central Nervous System | Analgesics |
|  | Antidepressant Drugs |
|  | Antiepileptic Drugs |
|  | CNS Stimulants and drugs used for ADHD |
|  | Dementia |
|  | Drugs Used In Nausea And Vertigo |
|  | Drugs Used In Park'ism/Related Disorders |
|  | Drugs Used In Psychoses \& Rel.Disorders |
|  | Drugs Used In Substance Dependence |
|  | Hypnotics And Anxiolytics |
|  | Obesity |
| Endocrine System | Corticosteroids (Endocrine) |
|  | Drugs Affecting Bone Metabolism |
|  | Drugs Used In Diabetes |
|  | Hypothalamic\&Pituitary Hormones\&Antioest |
|  | Other Endocrine Drugs |
|  | Thyroid And Antithyroid Drugs |
| Eye | Treatment Of Glaucoma |
| Gastro-Intestinal System | Antisecretory Drugs+Mucosal Protectants |
|  | Antispasmod.\&Other Drgs Alt.Gut Motility |
|  | Chronic Bowel Disorders |
|  | Drugs Affecting Intestinal Secretions |
|  | Dyspep\&Gastro-Oesophageal Reflux Disease |
| Infections | Antiviral Drugs |
| Malignant Disease \& Immunosuppression | Cytotoxic Drugs |
|  | Drugs Affecting The Immune Response |
|  | Sex Hormones \& Antag In Malig Disease |
| Musculoskeletal \& Joint Diseases | Drugs Used In Neuromuscular Disorders |
|  | Drugs Used In Rheumatic Diseases \& Gout |
|  | Soft-Tissue Disorders \& Topical Pain Rel |
| Nutrition And Blood | Anaemias + Other Blood Disorders |
|  | Metabolic Disorders |
| Respiratory System | Bronchodilators |
|  | Corticosteroids (Respiratory) |
|  | Cromoglycate,Rel,Leukotriene Antagonists |
|  | Mucolytics |
|  | Resp Stimulants \& Pulmonary Surfactants |
| Skin | Preparations For Eczema And Psoriasis |

Table 2: Summary statistics for chronic disease medication count at baseline in the UK Biobank

| Chronic disease medication count | Persons (\%) | Men (\%) | Women (\%) |
| :--- | :---: | :---: | :---: |
| None | 51.6 | 52.5 | 50.8 |
| $1-2$ | 39.7 | 37.7 | 41.4 |
| $>2$ | 8.7 | 9.8 | 7.8 |

Table 3: Repeated measures Pearson correlation coefficients adjusted for baseline age for each of the 74 candidate biomarkers, by sex

| Biomarker name | Men | Women |
| :---: | :---: | :---: |
| Diastolic blood pressure | 0.603 | 0.664 |
| Systolic blood pressure | 0.609 | 0.656 |
| Pulse rate | 0.652 | 0.636 |
| Apolipoprotein A | 0.753 | 0.716 |
| Apolipoprotein B | 0.628 | 0.686 |
| Lipoprotein (a) | 0.973 | 0.968 |
| High density lipoprotein cholesterol | 0.815 | 0.807 |
| Low density lipoprotein cholesterol | 0.614 | 0.664 |
| Triglycerides | 0.570 | 0.620 |
| Mean platelet volume | 0.836 | 0.838 |
| Platelet count | 0.725 | 0.746 |
| Platelet crit | 0.701 | 0.707 |
| Platelet distribution width | 0.649 | 0.640 |
| Log C-Reactive Protein | 0.543 | 0.656 |
| Blood glucose | 0.447 | 0.364 |
| HbA1c | 0.771 | 0.720 |
| Insulin-like growth factor 1 | 0.770 | 0.744 |
| Sex hormone-binding globulin | 0.832 | 0.745 |
| Testosterone | 0.641 | Not considered |
| Oestradiol* | Not considered | 0.094 |
| Haemoglobin concentration | 0.635 | 0.594 |
| HLS reticulocyte count | 0.551 | 0.588 |
| Immature reticulocyte fraction | 0.430 | 0.405 |
| Mean corpuscular volume | 0.748 | 0.716 |
| Mean reticulocyte volume | 0.546 | 0.506 |
| Mean spherical cell volume | 0.706 | 0.691 |
| Total red blood cell count | 0.732 | 0.718 |
| Red blood cell distribution width | 0.566 | 0.480 |
| Reticulocyte count | 0.326 | 0.311 |
| Mean corpuscular haemoglobin concentration | 0.251 | 0.198 |
| Nucleic red blood cell count* | 0.013 | 0.003 |
| Albumin | 0.453 | 0.465 |
| Alanine aminotransferase | 0.482 | 0.326 |
| Aspartate aminotransferase | 0.445 | 0.329 |
| Direct bilirubin | 0.699 | 0.708 |
| Total bilirubin | 0.764 | 0.740 |
| Gamma Glutamyltransferase | 0.682 | 0.615 |
| Heel bone density | 0.689 | 0.713 |
| Body mass index | 0.931 | 0.925 |
| Sitting height | 0.796 | 0.799 |
| Standing height | 0.986 | 0.984 |
| Hip circumference | 0.805 | 0.839 |
| Waist circumference | 0.823 | 0.829 |
| Waist-hip ratio | 0.664 | 0.653 |
| Weight | 0.944 | 0.930 |
| Body fat-free mass | 0.945 | 0.914 |
| Body fat mass | 0.902 | 0.906 |
| Body fat percentage | 0.859 | 0.869 |
| Metabolic rate | 0.949 | 0.928 |
| Hand grip strength/height | 0.615 | 0.515 |
| Alkaline Phosphatase | 0.743 | 0.689 |
| Calcium | 0.371 | 0.406 |
| Rheumatoid factor | 0.755 | 0.856 |
| Vitamin D | 0.558 | 0.547 |
| Reaction time test | 0.518 | 0.494 |
| Pairs matching test | 0.233 | 0.206 |
| Urinary microalbumin | 0.400 | 0.357 |
| Urinary sodium | 0.325 | 0.296 |
| Urinary creatinine | 0.267 | 0.288 |
| Urinary potassium | 0.232 | 0.251 |
| Urea | 0.573 | 0.542 |
| Creatinine | 0.653 | 0.671 |
| Cystatin C | 0.759 | 0.802 |
| Phosphate | 0.409 | 0.393 |
| Total protein | 0.494 | 0.492 |
| Urate | 0.719 | 0.780 |


| Forced expiratory volume in 1s/height | 0.503 | 0.502 |
| :--- | :--- | :--- |
| Forced vital capacity/height | 0.655 | 0.649 |
| Eosinophil count | 0.619 | 0.603 |
| Lymphocyte count | 0.859 | 0.646 |
| Monocyte count | 0.420 | 0.341 |
| Neutrophil count | 0.539 | 0.528 |
| Basophil count | 0.143 | 0.112 |
| Total white blood cell count | 0.787 | 0.593 |

* Biomarkers with correlation coefficients of <0.1

Both baseline and repeated measurements for these biomarkers were available for 2657-9444 men and 2213-9873 women
The 36 excluded biomarkers are: pulse pressure; total cholesterol; peak expiratory flow (spirometry); heel bone density measurements represented as: Broadband ultrasound attenuation, quantitative ultrasound index, speed of sound through heel; impedance devicemeasured weight; total mass, fat mass, fat free mass and fat percentage for: trunk, left leg, right leg, left arm, right arm; Metabolic Equivalent Task (MET) minutes per week for moderate activity; MET minutes per week for vigorous activity; mean corpuscular haemoglobin; haematocrit percentage; visual acuity; hearing test; numeric memory test; fluid intelligence test; and prospective memory test.

Table 4: Missingness and Pearson correlations of best measure and supplemented lung function baseline and repeated measurements

| Men: | Forced expiratory volume in 1s (FEV1) |  |  |  | Forced vital capacity (FVC) |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Participants at baseline |  | Participants with 'accept' flagged repeat assessment |  | Participants at baseline |  | Participants with 'accept' flagged repeat assessment |  |
|  | Number | \% total | Correlation | Number | Number | \% total | Correlation | Number |
| Best measure | 158,140 | 72\% | 0.722 | 5888 | 158,140 | 72\% | 0.729 | 5888 |
| Remainder with 'accept' flags | 9,113 | 4\% | 0.753 | 140 | 9,113 | 4\% | 0.828 | 140 |
| All remaining readings | 31,125 | 14\% | 0.654 | 664 | 31,125 | 14\% | 0.664 | 664 |
| All readings | 198,378 | 90\% | 0.720 | 6692 | 198,378 | 90\% | 0.729 | 6692 |
| No data | 20,870 | 10\% |  |  | 20,870 | 10\% |  |  |
| Women: | Forced expiratory volume in 1s (FEV1) |  |  |  | Forced vital capacity (FVC) |  |  |  |
|  | Participants at baseline |  | Participants with 'accept' flagged repeat assessment |  | Participants at baseline |  | Participants with 'accept' flagged repeat assessment |  |
|  | Number | \% total | Correlation | Number | Number | \% total | Correlation | Number |
| Best measure | 183,323 | 70\% | 0.723 | 5978 | 183,323 | 70\% | 0.743 | 5978 |
| Remainder with 'accept' flags | 9,710 | 4\% | 0.762 | 127 | 9,710 | 4\% | 0.778 | 127 |
| All remaining readings | 46,423 | 18\% | 0.585 | 747 | 46,423 | 18\% | 0.614 | 747 |
| All readings | 239,456 | 92\% | 0.709 | 6852 | 239,456 | 92\% | 0.730 | 6852 |
| No data | 21,315 | 8\% |  |  | 21,315 | 8\% |  |  |

Best measure lung function measurements were defined by UK Biobank. ${ }^{2}$ Two types of lung function measurements were used to supplement best measure lung function: (1) remainder with 'accept' flags and (2) all remaining readings.

Table 5: List of the 72 UK Biobank biomarkers selected for analysis, with percentage of missing data for each biomarker in the whole population

| No. | Body system group | Biomarker description | \% missing |
| :---: | :---: | :---: | :---: |
| 1 | Cardiovascular: | Diastolic blood pressure | 0.1 |
| 2 |  | Systolic blood pressure | 0.1 |
| 3 |  | Pulse rate | 0.1 |
| 4 |  | Apolipoprotein A | 12.9 |
| 5 |  | Apolipoprotein B | 5 |
| 6 |  | Lipoprotein (a) | 7.6 |
| 7 |  | High density lipoprotein cholesterol | 12.7 |
| 8 |  | Low density lipoprotein cholesterol | 4.9 |
| 9 |  | Triglycerides | 4.7 |
| 10 | Clotting: | Mean platelet volume | 2.9 |
| 11 |  | Platelet count | 2.9 |
| 12 |  | Platelet crit | 2.9 |
| 13 |  | Platelet distribution width | 2.9 |
| 14 | Endocrine, metabolic | Log C-Reactive Protein | 4.8 |
| 15 | and immune: | Blood glucose | 12.8 |
| 16 |  | HbA1c | 5.3 |
| 17 |  | Insulin-like growth factor 1 | 5.2 |
| 18 |  | Sex hormone-binding globulin | 13.4 |
| 19 |  | Testosterone | 5.6 |
| 20 | Liver: | Albumin | 12.7 |
| 21 |  | Alanine aminotransferase | 4.7 |
| 22 |  | Aspartate aminotransferase | 5.1 |
| 23 |  | Direct bilirubin | 7.5 |
| 24 |  | Total bilirubin | 5.1 |
| 25 |  | Gamma Glutamyltransferase | 4.7 |
| 26 | Musculoskeletal: | Heel bone density | 1.8 |
| 27 |  | Body mass index* | 0.4 |
| 28 |  | Sitting height* | 0.3 |
| 29 |  | Standing height* | 0.3 |
| 30 |  | Hip circumference* | 0.2 |
| 31 |  | Waist circumference* | 0.2 |
| 32 |  | Waist-hip ratio* | 0.2 |
| 33 |  | Weight* | 0.3 |
| 34 |  | Body fat-free mass* | 1.8 |
| 35 |  | Body fat mass* | 1.9 |
| 36 |  | Body fat percentage* | 1.8 |
| 37 |  | Metabolic rate* | 1.8 |
| 38 |  | Hand grip strength/height* | 0.4 |
| 39 |  | Alkaline Phosphatase | 4.7 |
| 40 |  | Calcium | 12.7 |
| 41 |  | Rheumatoid factor | 4.7 |
| 42 |  | Vitamin D | 8.5 |
| 43 | Nervous: | Reaction time test | 1.1 |
| 44 |  | Pairs matching test | 3.5 |
| 45 | Red blood cells: | Haemoglobin concentration | 2.9 |
| 46 |  | HLS reticulocyte count | 4.6 |
| 47 |  | Immature reticulocyte fraction | 4.6 |
| 48 |  | Mean corpuscular volume | 2.9 |
| 49 |  | Mean reticulocyte volume | 4.6 |
| 50 |  | Mean spherical cell volume | 4.6 |
| 51 |  | Total red blood cell count | 2.9 |
| 52 |  | Red blood cell distribution width | 2.9 |
| 53 |  | Reticulocyte count | 4.6 |
| 54 |  | Mean corpuscular haemoglobin concentration | 2.9 |
| 55 | Renal: | Urinary microalbumin | 2.9 |
| 56 |  | Urinary sodium | 2.9 |
| 57 |  | Urinary creatinine | 2.7 |
| 58 |  | Urinary potassium | 2.9 |
| 59 |  | Urea | 4.8 |
| 60 |  | Creatinine | 4.7 |
| 61 |  | Cystatin C | 4.7 |
| 62 |  | Phosphate | 12.8 |
| 63 |  | Total protein | 12.8 |
| 64 |  | Urate | 4.8 |
| 65 | Respiratory: | Forced expiratory volume in 1s/height* | 8.9 |
| 66 |  | Forced vital capacity/height* | 8.9 |


| 67 | White blood cells: | Eosinophil count | 3.1 |
| :--- | :--- | :--- | :--- |
| 68 | Lymphocyte count | 3.1 |  |
| 69 |  | Monocyte count | 3.1 |
| 70 |  | Neutrophil count | 3.1 |
| 71 |  | Basophil count | 3.1 |
| 72 | Total white blood cell count | 2.9 |  |

* Values were standardised separately for men and women, due to large sex differences

All biochemical biomarkers were measured via blood assays unless labelled as 'urinary'

Table 6: Constituent ICD-10 codes for the age-related hospital admissions definition, ranked by hazard ratio of baseline age in the UK Biobank

| No | ICD10 group | ICD-10 codes | Incident cases in UK Biobank | Hazard ratio for 10 years of age |
| :---: | :---: | :---: | :---: | :---: |
| 1 | Dementia | F00 F01 F03 G30 | 214 | 5.70 |
| 2 | Parkinsons | G20 | 576 | 3.16 |
| 3 | Chronic renal failure | N18 | 873 | 3.14 |
| 4 | Osteoporosis without pathological fracture | M81 | 1454 | 2.66 |
| 5 | Other disorders of fluid, electrolyte and acid-base balance | E87 | 554 | 2.29 |
| 6 | Retention of urine | R33 | 1274 | 2.28 |
| 7 | Transient cerebral ischaemic attacks and related syndromes | G45 | 508 | 2.27 |
| 8 | Delirium | F05 | 54 | 2.27 |
| 9 | Polyarthrosis | M15 | 913 | 2.19 |
| 10 | Respiratory disease not infection | J69 J96 | 412 | 2.17 |
| 11 | Cerebrovascular | 167169 | 794 | 2.11 |
| 12 | Osteoporosis | M80 | 546 | 2.07 |
| 13 | Cerebral Infarction | 163 | 574 | 2.07 |
| 14 | Other hearing loss | H91 | 864 | 2.00 |
| 15 | Other abnormal findings of blood chemistry | R79 | 1816 | 1.90 |
| 16 | Renal failure | N17 N19 | 956 | 1.90 |
| 17 | Neurodegenerative disease | G31 | 114 | 1.90 |
| 18 | Problems related to social environment | Z60 | 839 | 1.86 |
| 19 | Skin ulcer | L89 L97 | 308 | 1.83 |
| 20 | Kidney urinary disorders | N28 | 876 | 1.82 |
| 21 | Other arthrosis | M19 | 4403 | 1.80 |
| 22 | Spinal stenosis (secondary code only) | M48 | 1038 | 1.73 |
| 23 | Digestive disease | K26 | 1567 | 1.65 |
| 24 | Pneumonia, organism unspecified | J18 | 1256 | 1.60 |
| 25 | Blindness or low vision | H54 | 381 | 1.60 |
| 26 | Dorsophathy | M41 | 379 | 1.59 |
| 27 | Fall on same level from slipping, tripping and stumbling | W01 | 1597 | 1.59 |
| 28 | Unspecified fall | W19 | 926 | 1.57 |
| 29 | Hypotension | 195 | 717 | 1.51 |
| 30 | Syncope and collapse | R55 | 1541 | 1.49 |
| 31 | Metabolic disorder | E83 E86 | 1135 | 1.47 |
| 32 | Cognition emotion behaviour symptoms | R40 R41 R44 R45 R47 | 1577 | 1.47 |
| 33 | Symptoms and signs concerning food and fluid intake | R63 | 1405 | 1.45 |
| 34 | Other external | Y84 Y95 Z22 Z50 Z73 Z74 Z75 Z93 Z99 | 3954 | 1.44 |
| 35 | Hemiplegia | G81 | 381 | 1.43 |
| 36 | Fall | W06 W18 | 850 | 1.39 |
| 37 | Urinary system symptoms | R32 | 918 | 1.37 |
| 38 | Unspecified acute lower respiratory infection | J22 | 998 | 1.36 |
| 39 | Nervous and musculoskeletal symptoms | R26 R29 | 1000 | 1.35 |
| 40 | Other bacterial agents as the cause of diseases classified to other chapters (secondary code) | B96 | 1051 | 1.33 |
| 41 | Fall on and from stairs and steps | W10 | 639 | 1.32 |
| 42 | Unspecified haematuria | R31 | 3447 | 1.31 |
| 43 | Abnormalities of heart beat | R00 | 1939 | 1.30 |
| 44 | Personal history of other diseases and conditions | Z87 | 6111 | 1.26 |
| 45 | Skin infection | L08 | 627 | 1.26 |
| 46 | Infection | A04 A41 B95 | 3444 | 1.25 |
| 47 | Other anaemias | D64 | 2237 | 1.25 |
| 48 | Dysphagia | R13 | 1554 | 1.25 |
| 49 | Pancreatic disorder | E16 | 230 | 1.23 |
| 50 | Abnormal results of function studies | R94 | 755 | 1.22 |
| 51 | Other functional intestinal disorders | K59 | 1955 | 1.22 |
| 52 | Gangrene | RO2 | 137 | 1.22 |

This codelist excludes cancer or any form of neoplasms
P-values of hazard ratios for 10 years of age for each ICD-10 group were significant at the $10^{-3}$ level

Table 7: Number of events for each outcome in each prior health subpopulation, by sex

|  | Persons | Men | Women |
| :--- | :---: | :---: | :---: |
| Healthy subpopulation |  |  |  |
| Participants at baseline | 141,254 | 65,869 | 75,385 |
| Deaths from chronic disease | 2,394 | 1,357 | 1,037 |
| Prior CHD event | 0 | 0 | 0 |
| Incident CHD event | 2,693 | 1,987 | 706 |
| Prior age-related hospital admissions | 6,206 | 2,953 | 3,253 |
| Incident age-related hospital admissions | 21,627 | 10,317 | 11,310 |
| Poor health subpopulation |  |  |  |
| Participants at baseline | 82,835 | 42,277 | 40,558 |
| Deaths from chronic disease | 7,552 | 4,729 | 2,823 |
| Prior CHD event | 12,986 | 9,942 | 3,044 |
| Incident CHD event | 6,296 | 4,090 | 2,206 |
| Prior age-related hospital admissions | 35,947 | 18,327 | 17,620 |
| Incident age-related hospital admissions | 19,254 | 10,023 | 9,231 |
| Whole population |  |  |  |
| Participants at baseline | 480,019 | 219,248 | 260,771 |
| Deaths from chronic disease | 18,799 | 11,362 | 7,437 |
| Prior CHD event | 12,986 | 9,942 | 3,044 |
| Incident CHD event | 18,757 | 12,676 | 6,081 |
| Prior age-related hospital admissions | 74,811 | 35,401 | 39,410 |
| Incident age-related hospital admissions | 93,716 | 43,700 | 50,016 |

Table 8: Pearson correlation coefficients of biomarkers with chronological age ranked by magnitude, in the Healthy subpopulation, by sex

## Healthy men

| Ranking | Biomarker | Pearson <br> correlation <br> coefficient |
| :--- | :--- | :---: |
| 1 |  | -0.377 |
| 2 | Forced expiratory volume in 1s/height | 0.317 |
| 3 | Cystatin C | 0.315 |
| 4 | Sex hormone-binding globulin | -0.313 |
| 5 | Sysed vital capacity/height | 0.295 |
| 6 | Albumin blood pressure | -0.283 |
| 7 | Reaction time test | -0.281 |
| 8 | Insulin-like growth factor 1 | -0.259 |
| 9 | Hand grip strength/height | -0.238 |
| 10 | Metabolic rate | -0.224 |
| 11 | Body fat-free mass | -0.214 |
| 12 | HbA1c | 0.208 |
| 13 | Mean corpuscular volume | 0.186 |
| 14 | Sitting height | -0.177 |
| 15 | Pairs matching test | -0.169 |
| 16 | Waist-hip ratio | 0.167 |
| 17 | Mean spherical cell volume | 0.166 |
| 18 | Urea | 0.159 |
| 19 | Body fat percentage | 0.151 |
| 20 | Standing height | -0.148 |
| 21 | Total protein | -0.146 |
| 22 | Red blood cell distribution width | 0.145 |
| 23 | Alanine aminotransferase | -0.140 |
| 24 | Apolipoprotein A | 0.139 |
| 25 | Mean reticulocyte volume | 0.135 |
| 26 | Monocyte count | 0.126 |
| 27 | Log C-Reactive Protein | 0.125 |
| 28 | Total red blood cell count | -0.125 |
| 29 | Blood glucose | 0.122 |
| 30 | Calcium | -0.120 |
| 31 | Urinary sodium | -0.119 |
| 32 | Vitamin D | 0.118 |
| 33 | Urinary microalbumin | 0.118 |
| 34 | Platelet crit | -0.102 |
| 35 | Neutrophil count | 0.102 |
|  |  |  |
|  |  |  |

Healthy women

| Ranking | Biomarker | Pearson <br> correlation <br> coefficient |
| :--- | :--- | :---: |
| 1 |  | -0.441 |
| 2 | Forced expiratory volume in 1s/height | 0.404 |
| 3 | Cystatin C | -0.381 |
| 4 | Forced vital capacity/height | 0.373 |
| 5 | Systolic blood pressure | 0.359 |
| 6 | Low density lipoprotein | 0.342 |
| 7 | HbA1c | 0.336 |
| 8 | Apolipoprotein B | 0.328 |
| 9 | Alkaline Phosphatase | -0.318 |
| 10 | Hand grip strength/height | 0.317 |
| 11 | Urea | -0.309 |
| 12 | Insulin-like growth factor 1 | -0.308 |
| 13 | Reaction time test | 0.235 |
| 14 | Triglycerides | -0.233 |
| 15 | Heel bone density | -0.217 |
| 16 | Sitting height | 0.200 |
| 17 | Aspartate aminotransferase | 0.192 |
| 18 | Urate | 0.185 |
| 19 | Haemoglobin concentration | -0.184 |
| 20 | Metabolic rate | 0.182 |
| 21 | Blood glucose | 0.179 |
| 22 | Calcium | -0.178 |
| 23 | Body fat-free mass | -0.169 |
| 24 | Standing height | -0.159 |
| 25 | Pairs matching test | 0.153 |
| 26 | Waist-hip ratio | 0.151 |
| 27 | Body fat percentage | 0.148 |
| 28 | Apolipoprotein A | 0.144 |
| 29 | Phosphate | 0.138 |
| 30 | Log C-Reactive Protein | 0.127 |
| 31 | Alanine aminotransferase | 0.127 |
| 32 | Total red blood cell count | -0.127 |
| 33 | Direct bilirubin | 0.126 |
| 34 | Gamma Glutamyltransferase | -0.125 |
| 35 | Urinary sodium | 0.118 |
|  | Urinary microalbumin |  |
|  |  |  |
|  |  |  |


| 36 | High density lipoprotein | 0.102 | 36 | Waist circumference | 0.108 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 37 | Weight | -0.093 | 37 | Diastolic blood pressure | 0.107 |
| 38 | Total white blood cell count | 0.086 | 38 | Testosterone | -0.103 |
| 39 | Apolipoprotein B | 0.085 | 39 | High density lipoprotein | 0.102 |
| 40 | Urinary creatinine | -0.085 | 40 | Urinary creatinine | -0.092 |
| 41 | Diastolic blood pressure | 0.083 | 41 | Neutrophil count | -0.089 |
| 42 | Waist circumference | 0.082 | 42 | Vitamin D | 0.087 |
| 43 | Low density lipoprotein | 0.079 | 43 | Platelet crit | -0.084 |
| 44 | Platelet count | -0.073 | 44 | Body fat mass | 0.062 |
| 45 | Reticulocyte count | -0.065 | 45 | Mean platelet volume | -0.060 |
| 46 | Body fat mass | 0.057 | 46 | Mean spherical cell volume | 0.060 |
| 47 | Phosphate | -0.054 | 47 | Mean corpuscular volume | 0.058 |
| 48 | Alkaline Phosphatase | 0.054 | 48 | Sex hormone-binding globulin | -0.056 |
| 49 | Basophil count | 0.047 | 49 | Lymphocyte count | 0.055 |
| 50 | HLS reticulocyte count | -0.047 | 50 | Body mass index | 0.054 |
| 51 | Heel bone density | -0.042 | 51 | Total white blood cell count | -0.054 |
| 52 | Mean corpuscular haemoglobin concentration | -0.041 | 52 | Albumin | -0.053 |
| 53 | Aspartate aminotransferase | -0.040 | 53 | Pulse rate | 0.052 |
| 54 | Pulse rate | 0.039 | 54 | Lipoprotein (a) | 0.049 |
| 55 | Hip circumference | -0.038 | 55 | Total protein | -0.043 |
| 56 | Rheumatoid factor | 0.036 | 56 | Platelet count | -0.043 |
| 57 | Direct bilirubin | -0.035 | 57 | Total bilirubin | -0.040 |
| 58 | Platelet distribution width | 0.034 | 58 | Mean reticulocyte volume | 0.039 |
| 59 | Mean platelet volume | -0.034 | 59 | Basophil count | -0.039 |
| 60 | Haemoglobin concentration | -0.032 | 60 | Creatinine | 0.038 |
| 61 | Creatinine | 0.029 | 61 | Platelet distribution width | 0.035 |
| 62 | Lymphocyte count | -0.026 | 62 | Rheumatoid factor | 0.031 |
| 63 | Total bilirubin | -0.018 | 63 | Weight | -0.023 |
| 64 | Body mass index | -0.018 | 64 | Monocyte count | 0.021 |
| 65 | Urinary potassium | 0.013 | 65 | Hip circumference | 0.021 |
| 66 | Testosterone | -0.010 | 66 | Urinary potassium | 0.013 |
| 67 | Immature reticulocyte fraction | 0.007 | 67 | Eosinophil count | -0.012 |
| 68 | Urate | 0.006 | 68 | Immature reticulocyte fraction | -0.009 |
| 69 | Triglycerides | 0.006 | 69 | Reticulocyte count | 0.007 |
| 70 | Gamma Glutamyltransferase | -0.003 | 70 | Red blood cell distribution width | 0.007 |
| 71 | Lipoprotein (a) | -0.002 | 71 | Mean corpuscular haemoglobin concentration | 0.006 |
| 72 | Eosinophil count | 0.001 | 72 | HLS reticulocyte count | -0.002 |

Table 9: Model coefficients for (A) Klemera Doubal (KDM) and (B) stepwise regression biological ages, in the Healthy subpopulation, by sex
(A) Klemera Doubal (KDM) ages

| Biomarker principal component number and description |  | Healthy men |  |  | Healthy women |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\mathrm{q}_{\mathrm{j}}$ | $\mathrm{k}_{\mathrm{j}}$ | $\mathrm{s}_{\mathrm{j}}$ | $\mathrm{q}_{\mathrm{j}}$ | $\mathrm{k}_{\mathrm{j}}$ | $\mathrm{S}_{\mathrm{j}}$ |
| PC1 | General adiposity | 55.224 | 0.004 | 11.865 | 56.673 | -1.035 | 10.628 |
| PC2 | Total haemoglobin volume | 56.276 | 1.035 | 11.814 | 58.763 | -3.455 | 10.344 |
| PC3 | Height | 56.007 | 3.638 | 10.626 | 56.429 | 3.049 | 10.038 |
| PC4 | Albumin | 56.235 | 5.479 | 10.676 | 55.896 | -0.074 | 10.896 |
| PC5 | Neutrophil count | 55.806 | -1.896 | 11.633 | 56.036 | -0.543 | 10.875 |
| PC6 | Immature red blood cell volume | 55.353 | -2.078 | 11.565 | 55.880 | 0.151 | 10.894 |
| PC7 | LDL and ApoB | 55.047 | -0.746 | 11.824 | 55.293 | -4.247 | 9.166 |
| PC8 | Reticulocyte count | 55.226 | 0.055 | 11.865 | 56.530 | -1.526 | 10.739 |
| PC9 | Urinary potassium and creatinine | 55.248 | -0.101 | 11.864 | 55.950 | 0.251 | 10.893 |
| PC10 | Blood pressure | 54.700 | -2.940 | 11.374 | 56.959 | -3.768 | 9.829 |
| PC11 | HDL and ApoA | 55.715 | 0.980 | 11.811 | 55.797 | 0.126 | 10.895 |
| PC12 | Aminotransferases | 55.303 | 0.325 | 11.860 | 57.384 | -4.235 | 10.206 |
| PC13 | Bilirubin | 55.759 | 1.016 | 11.774 | 55.432 | 1.558 | 10.719 |
| PC14 | Platelet count | 55.067 | -0.343 | 11.858 | 55.798 | 0.319 | 10.888 |
| PC15 | Red blood cell haemoglobin concentration | 55.442 | -1.244 | 11.798 | 55.889 | -0.048 | 10.896 |
| PC16 | Testosterone | 54.896 | -0.385 | 11.862 | 56.129 | -0.345 | 10.896 |
| PC17 | Lung function/height | 57.442 | -5.247 | 9.508 | 57.285 | -4.819 | 8.697 |
| PC18 | Blood glucose | 55.467 | 2.362 | 11.694 | 56.254 | 3.519 | 10.508 |
| PC19 | Platelet cell volume | 55.216 | -0.181 | 11.864 | 55.929 | -0.722 | 10.869 |
| PC20 | LP(a) | 55.233 | 0.081 | 11.865 | 55.886 | 0.906 | 10.858 |
| PC21 | Pairs matching test | 55.541 | -3.107 | 11.464 | 56.001 | -2.285 | 10.670 |
| PC22 | Rheumatoid factor | 55.234 | 0.597 | 11.851 | 55.898 | 0.455 | 10.887 |
| PC23 | Bone density | 55.485 | -0.830 | 11.836 | 55.451 | -2.792 | 10.587 |
| PC24 | Vitamin D | 55.180 | 0.897 | 11.832 | 55.882 | 0.242 | 10.893 |
| PC25 | IGF-1 | 56.478 | 5.561 | 10.692 | 56.011 | 3.770 | 10.242 |
| PC26 | Urinary microalbumin | 55.491 | 3.197 | 11.636 | 56.257 | 2.829 | 10.767 |
| PC27 | Basophil count | 55.356 | 1.306 | 11.809 | 55.893 | -0.153 | 10.895 |
| PC28 | Central adiposity | 56.393 | -4.109 | 11.274 | 56.605 | -3.698 | 10.338 |
| PC29 | Eosinophil count | 55.214 | 0.838 | 11.836 | 56.041 | 0.829 | 10.869 |
| PC30 | Alkaline phosphatase | 55.614 | -2.022 | 11.738 | 56.426 | -5.813 | 9.215 |
| PC31 | Pulse rate | 55.576 | -1.408 | 11.783 | 55.926 | -1.888 | 10.763 |
| PC32 | Red blood cell width | 55.694 | -3.190 | 11.552 | 55.904 | -0.203 | 10.894 |
| PC33 | Reaction time test | 56.417 | -5.222 | 10.788 | 55.963 | -4.210 | 10.109 |
| PC34 | Sex hormone-binding globulin | 58.143 | 7.049 | 11.096 | 56.932 | -2.355 | 10.600 |
| PC35 | Hand grip strength/height | 56.156 | 5.354 | 10.716 | 56.783 | 5.022 | 9.845 |
| PC36 | Phosphate | 54.881 | 1.169 | 11.806 | 55.469 | -2.109 | 10.724 |
| PC37 | Lymphocyte count | 55.340 | -0.547 | 11.855 | 55.902 | -2.055 | 10.722 |
| PC38 | Triglycerides | 55.226 | 0.008 | 11.865 | 57.879 | 6.395 | 9.838 |
| PC39 | Urinary sodium | 55.393 | 0.634 | 11.847 | 55.754 | 0.477 | 10.888 |
| PC40 | Monocyte count | 54.981 | 2.936 | 11.544 | 56.276 | 1.301 | 10.841 |
| PC41 | Gamma glutamyltransferase | 55.145 | 0.680 | 11.847 | 57.554 | 4.670 | 10.325 |
| PC42 | Urea | 54.943 | 2.177 | 11.690 | 56.967 | 4.759 | 9.985 |
| PC43 | HbA1c | 56.395 | 4.928 | 11.232 | 57.306 | 6.937 | 9.638 |
| PC44 | Platelet distribution width | 55.217 | 0.071 | 11.865 | 55.964 | 0.583 | 10.882 |
| PC45 | Log C-reactive protein | 56.097 | 4.298 | 11.264 | 56.620 | 4.315 | 10.172 |
| PC46 | Reticulocyte fraction | 55.424 | 1.087 | 11.821 | 56.028 | 0.913 | 10.862 |
| PC47 | Cystatin C | 55.163 | -6.091 | 10.883 | 58.861 | -7.437 | 9.137 |
| PC48 | Muscle mass | 55.919 | -6.416 | 10.722 | 56.018 | -4.356 | 10.485 |
| PC49 | Calcium | 55.023 | -3.212 | 11.488 | 55.788 | 3.217 | 10.429 |
| PC50 | Total protein | 55.330 | 2.042 | 11.695 | 55.903 | -1.683 | 10.770 |
| PC51 | Urate | 54.829 | 0.870 | 11.845 | 59.192 | 6.360 | 9.978 |

$q_{j}=$ intercept, $k_{j}=$ coefficient and $s_{j}=$ square root of residual variance for the $j^{\text {th }}$ biomarker component

| Biomarker principal component number and description |  | Healthy men | Healthy women |
| :---: | :---: | :---: | :---: |
|  |  | Coefficients |  |
| (Intercept) |  | 59.015 | 55.942 |
| PC1 | General adiposity | 0.189 | 0.146 |
| PC2 | Total haemoglobin volume | 0.491 | -0.264 |
| PC3 | Height | -0.288 | - |
| PC4 | Albumin | 1.017 | 0.410 |
| PC5 | Neutrophil count | -0.423 | 0.225 |
| PC6 | Immature red blood cell volume | -0.398 | -0.312 |
| PC7 | LDL and ApoB | -0.455 | -0.720 |
| PC8 | Reticulocyte count | 0.156 | 0.087 |
| PC9 | Urinary potassium and creatinine | 0.332 | 0.203 |
| PC10 | Blood pressure | -1.255 | -0.988 |
| PC11 | HDL and ApoA | 0.570 | 0.513 |
| PC12 | Aminotransferases | 0.397 | -0.182 |
| PC13 | Bilirubin | -0.134 | - |
| PC14 | Platelet count | -0.520 | -0.314 |
| PC15 | Red blood cell haemoglobin concentration | - | 0.084 |
| PC16 | Testosterone | 0.687 | 1.556 |
| PC17 | Lung function/height | -1.103 | -1.030 |
| PC18 | Blood glucose | 0.401 | 0.486 |
| PC19 | Platelet cell volume | -0.432 | -0.247 |
| PC20 | LP(a) | - | - |
| PC21 | Pairs matching test | -0.520 | -0.379 |
| PC22 | Rheumatoid factor | 0.154 | 0.066 |
| PC23 | Bone density | -0.128 | -0.825 |
| PC24 | Vitamin D | 0.682 | 0.512 |
| PC25 | IGF-1 | 0.822 | 1.218 |
| PC26 | Urinary microalbumin | 0.312 | 0.617 |
| PC27 | Basophil count | - | -0.111 |
| PC28 | Central adiposity | -0.860 | -0.176 |
| PC29 | Eosinophil count | -0.186 | -0.250 |
| PC30 | Alkaline phosphatase | -0.106 | -0.790 |
| PC31 | Pulse rate | 0.119 | - |
| PC32 | Red blood cell width | -0.422 | - |
| PC33 | Reaction time test | -1.042 | -0.918 |
| PC34 | Sex hormone-binding globulin | 2.661 | -0.075 |
| PC35 | Hand grip strength/height | 0.430 | 0.679 |
| PC36 | Phosphate | 0.180 | -0.283 |
| PC37 | Lymphocyte count | 0.395 | - |
| PC38 | Triglycerides | 0.416 | 0.441 |
| PC39 | Urinary sodium | 1.056 | 1.067 |
| PC40 | Monocyte count | 0.472 | 0.187 |
| PC41 | Gamma glutamyltransferase | -0.113 | -0.265 |
| PC42 | Urea | 0.801 | 1.110 |
| PC43 | HbA1c | 0.918 | 1.382 |
| PC44 | Platelet distribution width | 0.328 | 0.116 |
| PC45 | Log C-reactive protein | -0.199 | -0.289 |
| PC46 | Reticulocyte fraction | -0.187 | -0.212 |
| PC47 | Cystatin C | -1.774 | -1.483 |
| PC48 | Muscle mass | -1.182 | -0.519 |
| PC49 | Calcium | 0.139 | 0.660 |
| PC50 | Total protein | 0.757 | 1.189 |
| PC51 | Urate | -0.398 | -0.490 |

Table 10: Importances of the 51 biomarker principal components in the Klemera Doubal (KDM) ages for healthy men (left) and women (right)

Healthy men

| Rank | Biomarker principal component | Proportion of total $\mathbf{R}^{2}$ (\%) |
| :---: | :---: | :---: |
| 1 | Lung function/height | 12.4 |
| 2 | Reaction time test | 6.9 |
| 3 | IGF-1 | 6.7 |
| 4 | Cystatin C | 6.7 |
| 5 | Hand grip strength/height | 6.4 |
| 6 | Albumin | 6.3 |
| 7 | Sex hormone-binding globulin | 6.0 |
| 8 | Muscle mass | 5.9 |
| 9 | Height | 5.6 |
| 10 | Blood pressure | 3.5 |
| 11 | HbA1c | 3.5 |
| 12 | Central adiposity | 2.9 |
| 13 | Pairs matching test | 2.6 |
| 14 | Log C-reactive protein | 2.5 |
| 15 | Calcium | 2.1 |
| 16 | Immature red blood cell volume | 2.0 |
| 17 | Red blood cell width | 1.8 |
| 18 | Total protein | 1.7 |
| 19 | Monocyte count | 1.5 |
| 20 | Urea | 1.5 |
| 21 | Urinary microalbumin | 1.4 |
| 22 | Blood glucose | 1.2 |
| 23 | Neutrophil count | 1.1 |
| 24 | HDL and ApoA | 0.8 |
| 25 | Vitamin D | 0.6 |
| 26 | Alkaline phosphatase | 0.6 |
| 27 | Total haemoglobin volume | 0.6 |
| 28 | General adiposity | 0.5 |
| 29 | Urinary sodium | 0.5 |
| 30 | LDL and ApoB | 0.4 |
| 31 | Phosphate | 0.4 |
| 32 | Pulse rate | 0.4 |
| 33 | Bilirubin | 0.4 |
| 34 | Red blood cell haemoglobin concentration | 0.3 |
| 35 | Testosterone | 0.3 |
| 36 | Platelet count | 0.3 |
| 37 | Basophil count | 0.3 |
| 38 | Urate | 0.2 |
| 39 | Reticulocyte count | 0.2 |
| 40 | Bone density | 0.2 |
| 41 | Aminotransferases | 0.2 |
| 42 | Triglycerides | 0.2 |
| 43 | Reticulocyte fraction | 0.2 |
| 44 | Gamma glutamyltransferase | 0.1 |
| 45 | Rheumatoid factor | 0.1 |
| 46 | Eosinophil count | 0.1 |
| 47 | Lymphocyte count | 0.1 |
| 48 | Urinary potassium and creatinine | 0.1 |
| 49 | Platelet distribution width | 0.0 |
| 50 | Platelet cell volume | 0.0 |
| 51 | LP(a) | 0.0 |

Healthy women

| Rank | Biomarker principal component | Proportion of total $\mathrm{R}^{2}$ (\%) |
| :---: | :---: | :---: |
| 1 | Lung function/height | 10.3 |
| 2 | Cystatin C | 8.0 |
| 3 | LDL and ApoB | 7.0 |
| 4 | Alkaline phosphatase | 6.6 |
| 5 | HbA1c | 5.9 |
| 6 | Hand grip strength/height | 5.6 |
| 7 | Urea | 4.9 |
| 8 | Blood pressure | 4.9 |
| 9 | Reaction time test | 4.6 |
| 10 | IGF-1 | 4.0 |
| 11 | Height | 3.8 |
| 12 | Triglycerides | 3.7 |
| 13 | Urate | 3.2 |
| 14 | Aminotransferases | 2.8 |
| 15 | Log C-reactive protein | 2.2 |
| 16 | Bone density | 2.2 |
| 17 | Total haemoglobin volume | 2.1 |
| 18 | Gamma glutamyltransferase | 1.9 |
| 19 | Blood glucose | 1.9 |
| 20 | Central adiposity | 1.8 |
| 21 | Muscle mass | 1.8 |
| 22 | Calcium | 1.7 |
| 23 | Pairs matching test | 1.3 |
| 24 | Phosphate | 1.0 |
| 25 | Sex hormone-binding globulin | 0.8 |
| 26 | General adiposity | 0.8 |
| 27 | Urinary microalbumin | 0.7 |
| 28 | Bilirubin | 0.7 |
| 29 | Lymphocyte count | 0.5 |
| 30 | Pulse rate | 0.4 |
| 31 | Reticulocyte count | 0.4 |
| 32 | Total protein | 0.3 |
| 33 | HDL and ApoA | 0.3 |
| 34 | Urinary sodium | 0.3 |
| 35 | Albumin | 0.2 |
| 36 | LP(a) | 0.2 |
| 37 | Testosterone | 0.2 |
| 38 | Vitamin D | 0.2 |
| 39 | Monocyte count | 0.1 |
| 40 | Platelet cell volume | 0.1 |
| 41 | Platelet distribution width | 0.1 |
| 42 | Urinary potassium and creatinine | 0.1 |
| 43 | Neutrophil count | 0.1 |
| 44 | Reticulocyte fraction | 0.1 |
| 45 | Platelet count | 0.1 |
| 46 | Eosinophil count | 0.1 |
| 47 | Red blood cell width | 0.1 |
| 48 | Rheumatoid factor | 0.1 |
| 49 | Immature red blood cell volume | 0.1 |
| 50 | Basophil count | 0.0 |
| 51 | Red blood cell haemoglobin concentration | 0.0 |

Table 11: Relative contribution (as a percentage of the total contribution of biological and chronological ages) of Klemera Doubal (KDM) biological age and chronological age in explaining each health outcome, in (A) the main analysis (top) and (B) when using the reduced biomarker panel (bottom), for healthy men and women

## (A) Main analysis

|  | Death from chronic disease |  |  | CHD event or death |  |  | Age-related hospital admissions |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | CA alone | CA and BA | BA alone | CA <br> alone | CA and BA | BA alone | CA alone | CA and BA | BA <br> alone |
| Men |  |  |  |  |  |  |  |  |  |
| Healthy subset | 28.3 | 63.5 | 8.2 | 29.5 | 63.8 | 6.7 | 34.7 | 61.4 | 4.0 |
| Poor health subset | 1.9 | 39.4 | 58.8 | 12.6 | 53.5 | 33.9 | 17.7 | 59.5 | 22.8 |
| Whole population | 8.3 | 56.6 | 35.1 | 17.3 | 62.2 | 20.4 | 20.8 | 64.5 | 14.7 |
| Women |  |  |  |  |  |  |  |  |  |
| Healthy subset | 39.0 | 58.3 | 2.7 | 10.0 | 61.9 | 28.1 | 39.6 | 58.7 | 1.7 |
| Poor health subset | 4.7 | 44.2 | 51.1 | 7.1 | 44.2 | 48.7 | 7.2 | 54.2 | 38.6 |
| Whole population | 18.9 | 60.8 | 20.4 | 11.0 | 57.0 | 32.0 | 18.8 | 66.1 | 15.1 |

(B) Using the reduced biomarker panel

|  | Death from chronic disease |  |  | CHD event or death |  |  |  | Age-related hospital admissions |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | CA <br> alone | CA and <br> BA | BA <br> alone | CA <br> alone | CA and <br> BA | BA <br> alone | CA <br> alone | CA and <br> BA | BA <br> alone |  |
| Men | 47.0 | 49.9 | 3.1 | 37.1 | 55.7 | 7.2 | 50.0 | 48.2 | 1.9 |  |
| Healthy subset | 9.9 | 43.0 | 47.1 | 30.4 | 49.4 | 20.2 | 38.0 | 50.1 | 11.9 |  |
| Poor health subset | 23.0 | 55.2 | 21.9 | 34.4 | 54.3 | 11.3 | 42.5 | 51.7 | 5.8 |  |
| Whole population |  |  |  |  |  |  |  |  |  |  |
| Women | 35.0 | 60.3 | 4.7 | 9.3 | 61.1 | 29.7 | 39.8 | 58.2 | 2.0 |  |
| Healthy subset | 9.3 | 48.0 | 42.7 | 9.9 | 45.6 | 44.5 | 11.0 | 54.7 | 34.4 |  |
| Poor health subset | 20.4 | 61.3 | 18.3 | 12.8 | 58.4 | 28.8 | 21.2 | 65.1 | 13.6 |  |
| Whole population | 20.3 |  |  |  |  |  |  |  |  |  |

[^0]Table 12: Harrell's C-indices (with standard errors) for mortality score and biological ages, for each outcome and subpopulation in the main analysis (unadjusted)

|  | Death from chronic disease |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
|  | Mortality score | Stepwise <br> regression age | Klemera <br> Doubal age | Improvement of <br> Stepwise regression age <br> over mortality score | Improvement of <br> Klemera Doubal age <br> over mortality score |
| Men |  |  |  | -0.012 |  |
| Healthy subset | $0.701(0.0081)$ | $0.686(0.0081)$ | $0.689(0.0081)$ | -0.015 | -0.050 |
| Poor health subset | $0.737(0.0043)$ | $0.640(0.0043)$ | $0.687(0.0043)$ | -0.097 | -0.026 |
| Whole population | $0.762(0.0028)$ | $0.707(0.0028)$ | $0.736(0.0028)$ | -0.055 | -0.018 |
| Women |  |  |  | -0.013 | -0.071 |
| Healthy subset | $0.653(0.0092)$ | $0.640(0.0092)$ | $0.635(0.0092)$ | -0.104 | -0.038 |
| Poor health subset | $0.691(0.0056)$ | $0.587(0.0056)$ | $0.620(0.0056)$ | -0.056 |  |
| Whole population | $0.721(0.0034)$ | $0.665(0.0034)$ | $0.683(0.0034)$ |  |  |


|  | CHD event or death |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
|  | Chronological <br> age | Stepwise <br> regression age | Klemera <br> Doubal age | Improvement of <br> Stepwise regression age <br> over mortality score | Improvement of <br> Klemera Doubal age <br> over mortality score |
| Men |  |  |  |  |  |
| Healthy subset | $0.514(0.0066)$ | $0.658(0.0066)$ | $0.649(0.0066)$ | 0.144 | 0.135 |
| Poor health subset | $0.508(0.0046)$ | $0.605(0.0046)$ | $0.632(0.0046)$ | 0.097 | 0.124 |
| Whole population | $0.498(0.0026)$ | $0.663(0.0026)$ | $0.677(0.0026)$ | 0.165 | 0.179 |
| Women |  |  |  |  |  |
| Healthy subset | $0.602(0.0111)$ | $0.705(0.0111)$ | $0.711(0.0111)$ | 0.103 | 0.109 |
| Poor health subset | $0.520(0.0063)$ | $0.639(0.0063)$ | $0.687(0.0063)$ | 0.119 | 0.167 |
| Whole population | $0.513(0.0038)$ | $0.698(0.0038)$ | $0.729(0.0038)$ | 0.185 |  |


|  | Age-related hospital admissions |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
|  | Mortality score | Stepwise <br> regression age | Klemera <br> Doubal age | Improvement of <br> Stepwise regression age <br> over mortality score | Improvement of <br> Klemera Doubal age <br> over mortality score |
| Men |  |  |  | 0.112 | 0.111 |
| Healthy subset | $0.504(0.0029)$ | $0.616(0.0029)$ | $0.615(0.0029)$ | 0.076 | 0.09 |
| Poor health subset | $0.503(0.0030)$ | $0.579(0.0030)$ | $0.597(0.0030)$ | 0.120 |  |
| Whole population | $0.501(0.0014)$ | $0.621(0.0014)$ | $0.630(0.0014)$ |  |  |
| Women |  |  |  | 0.073 | 0.068 |
| Healthy subset | $0.518(0.0028)$ | $0.591(0.0028)$ | $0.586(0.0028)$ | 0.072 |  |
| Poor health subset | $0.510(0.0031)$ | $0.560(0.0031)$ | $0.582(0.0031)$ | 0.090 |  |
| Whole population | $0.506(0.0013)$ | $0.597(0.0013)$ | $0.605(0.0013)$ | 0.091 | 0.0 |

Table 13: Harrell's C-indices (with standard errors) for chronological age and biological ages, for each outcome and subpopulation in the ( $A$ ) main analysis (top) and when $(B)$ using the reduced biomarker panel (bottom) (adjusted for environmental factors and health behaviours)

## (A) Main analysis

|  | Death from chronic disease |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
|  | Chronological <br> age | Stepwise <br> regression age | Klemera <br> Doubal age | Klemera Doubal age <br> and Chronological age | Improvement of Klemera <br> Doubal over Chronological age |
| Men |  |  |  |  |  |
| Healthy subset | $0.724(0.0081)$ | $0.699(0.0081)$ | $0.702(0.0081)$ | $0.731(0.0081)$ | 0.007 |
| Poor health subset | $0.658(0.0043)$ | $0.674(0.0043)$ | $0.704(0.0043)$ | $0.705(0.0043)$ | 0.047 |
| Whole population | $0.725(0.0028)$ | $0.730(0.0028)$ | $0.746(0.0028)$ | $0.756(0.0028)$ | 0.031 |
| Women |  |  |  |  | 0.002 |
| Healthy subset | $0.688(0.0092)$ | $0.665(0.0092)$ | $0.660(0.0092)$ | $0.690(0.0092)$ | 0.025 |
| Poor health subset | $0.617(0.0056)$ | $0.620(0.0056)$ | $0.639(0.0056)$ | $0.642(0.0056)$ | 0.014 |
| Whole population | $0.699(0.0034)$ | $0.688(0.0034)$ | $0.697(0.0034)$ | $0.713(0.0034)$ |  |


|  | CHD event or death |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
|  | Chronological <br> age | Stepwise <br> regression age | Klemera <br> Doubal age | Klemera Doubal age <br> and Chronological age | Improvement of Klemera <br> Doubal over Chronological age |
| Men |  |  |  |  |  |
| Healthy subset | $0.683(0.0066)$ | $0.678(0.0066)$ | $0.671(0.0066)$ | $0.689(0.0066)$ | 0.006 |
| Poor health subset | $0.628(0.0046)$ | $0.628(0.0046)$ | $0.645(0.0046)$ | $0.650(0.0046)$ | 0.022 |
| Whole population | $0.699(0.0026)$ | $0.693(0.0026)$ | $0.702(0.0026)$ | $0.714(0.0026)$ | 0.015 |
| Women |  |  |  |  | 0.023 |
| Healthy subset | $0.720(0.0111)$ | $0.728(0.0111)$ | $0.733(0.0111)$ | $0.743(0.0111)$ | 0.031 |
| Poor health subset | $0.671(0.0063)$ | $0.677(0.0063)$ | $0.707(0.0063)$ | $0.710(0.0063)$ | 0.028 |
| Whole population | $0.739(0.0038)$ | $0.740(0.0038)$ | $0.759(0.0038)$ | $0.767(0.0038)$ |  |


|  | Age-related hospital admissions |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
|  | Chronological <br> age | Stepwise <br> regression age | Klemera <br> Doubal age | Klemera Doubal age <br> and Chronological age | Improvement of Klemera <br> Doubal over Chronological age |
| Men |  |  |  |  |  |
| Healthy subset | $0.660(0.0029)$ | $0.642(0.0029)$ | $0.640(0.0029)$ | $0.662(0.0029)$ | 0.002 |
| Poor health subset | $0.604(0.0030)$ | $0.596(0.0030)$ | $0.609(0.0030)$ | $0.615(0.0030)$ | 0.011 |
| Whole population | $0.677(0.0014)$ | $0.666(0.0014)$ | $0.673(0.0014)$ | $0.685(0.0014)$ | 0.008 |
| Women |  |  |  |  | 0.001 |
| Healthy subset | $0.633(0.0028)$ | $0.619(0.0028)$ | $0.614(0.0028)$ | $0.634(0.0028)$ | 0.013 |
| Poor health subset | $0.588(0.0031)$ | $0.586(0.0031)$ | $0.600(0.0031)$ | $0.601(0.0031)$ | 0.006 |
| Whole population | $0.656(0.0013)$ | $0.649(0.0013)$ | $0.653(0.0013)$ | $0.662(0.0013)$ |  |

## (B) Using the reduced biomarker panel

|  | Death from chronic disease |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
|  | Chronological <br> age | Stepwise <br> regression age | Klemera <br> Doubal age | Klemera Doubal age <br> and Chronological age | Improvement of Klemera <br> Doubal over Chronological age |
| Men |  |  |  |  |  |
| Healthy subset | $0.724(0.0081)$ | $0.690(0.0081)$ | $0.679(0.0081)$ | $0.726(0.0081)$ | 0.004 |
| Poor health subset | $0.658(0.0043)$ | $0.687(0.0043)$ | $0.682(0.0043)$ | $0.688(0.0043)$ | 0.044 |
| Whole population | $0.725(0.0028)$ | $0.727(0.0028)$ | $0.720(0.0028)$ | $0.742(0.0028)$ | 0.030 |
| Women |  |  |  |  | 0.002 |
| Healthy subset | $0.688(0.0092)$ | $0.665(0.0092)$ | $0.666(0.0092)$ | $0.691(0.0092)$ | 0.023 |
| Poor health subset | $0.617(0.0056)$ | $0.624(0.0056)$ | $0.633(0.0056)$ | $0.636(0.0056)$ | 0.012 |
| Whole population | $0.699(0.0034)$ | $0.691(0.0034)$ | $0.696(0.0034)$ | $0.712(0.0034)$ |  |


|  | CHD event or death |  |  |  |  |
| :--- | :--- | :--- | :--- | :---: | :---: |
|  | Chronological <br> age | Stepwise <br> regression age | Klemera <br> Doubal age | Klemera Doubal age <br> and Chronological age | Improvement of Klemera <br> Doubal over Chronological age |
| Men |  |  |  |  |  |
| Healthy subset | $0.683(0.0066)$ | $0.669(0.0066)$ | $0.664(0.0066)$ | $0.690(0.0066)$ | 0.007 |
| Poor health subset | $0.628(0.0046)$ | $0.626(0.0046)$ | $0.625(0.0046)$ | $0.639(0.0046)$ | 0.011 |
| Whole population | $0.699(0.0026)$ | $0.686(0.0026)$ | $0.683(0.0026)$ | $0.707(0.0026)$ | 0.008 |
| Women |  |  |  |  | 0.025 |
| Healthy subset | $0.720(0.0111)$ | $0.735(0.0111)$ | $0.735(0.0111)$ | $0.745(0.0111)$ | 0.035 |
| Poor health subset | $0.671(0.0063)$ | $0.695(0.0063)$ | $0.700(0.0063)$ | $0.706(0.0063)$ | 0.025 |
| Whole population | $0.739(0.0038)$ | $0.753(0.0038)$ | $0.754(0.0038)$ | $0.764(0.0038)$ |  |


|  | Age-related hospital admissions |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
|  | Chronological <br> age | Stepwise <br> regression age | Klemera <br> Doubal age | Klemera Doubal age <br> and Chronological age | Improvement of Klemera <br> Doubal over Chronological age |
| Men |  |  |  |  |  |
| Healthy subset | $0.660(0.0029)$ | $0.635(0.0029)$ | $0.628(0.0029)$ | $0.661(0.0029)$ | 0.001 |
| Poor health subset | $0.604(0.0030)$ | $0.597(0.0030)$ | $0.595(0.0030)$ | $0.609(0.0030)$ | 0.007 |
| Whole population | $0.677(0.0014)$ | $0.660(0.0014)$ | $0.655(0.0014)$ | $0.680(0.0014)$ | 0.007 |
| Women |  |  |  |  | 0.000 |
| Healthy subset | $0.633(0.0028)$ | $0.615(0.0028)$ | $0.614(0.0028)$ | $0.634(0.0028)$ | 0.012 |
| Poor health subset | $0.588(0.0031)$ | $0.592(0.0031)$ | $0.598(0.0031)$ | $0.600(0.0031)$ | 0.006 |
| Whole population | $0.656(0.0013)$ | $0.649(0.0013)$ | $0.652(0.0013)$ | $0.662(0.0013)$ |  |

Table 14: Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) checklist for this study

| Section/Topic | Item* |  | Checklist Item | Page |
| :---: | :---: | :---: | :---: | :---: |
| Title and abstract |  |  |  |  |
| Title | 1 | D; V | Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted. | p1 |
| Abstract | 2 | D; V | Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions. | p2-3 |
| Introduction |  |  |  |  |
| Background and objectives | 3 a | D; V | Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models. | S1 p7-9 |
|  | 3b | D; V | Specify the objectives, including whether the study describes the development or validation of the model or both. | p4-7 |
| Methods |  |  |  |  |
| Source of data | 4a | D; V | Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable. | S1 p3 |
|  | 4b | D; V | Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up. | S1 p3 |
| Participants | 5a | D; V | Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres. | S1 p3 |
|  | 5b | D;V | Describe eligibility criteria for participants. | S1 p3-4 |
|  | 5 c | D;V | Give details of treatments received, if relevant. | NA |
| Outcome | 6a | D; V | Clearly define the outcome that is predicted by the prediction model, including how and when assessed. | S1 p5-6 |
|  | 6b | D;V | Report any actions to blind assessment of the outcome to be predicted. | NA |
| Predictors | 7a | D; V | Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured. | S1 p5,7 |
|  | 7b | D;V | Report any actions to blind assessment of predictors for the outcome and other predictors. | NA |
| Sample size | 8 | D;V | Explain how the study size was arrived at. | S1 p3 |
| Missing data | 9 | D; V | Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method. | S1 p3,5 |
| Statistical analysis methods | 10a | D | Describe how predictors were handled in the analyses. | S1 p7-9 |
|  | 10b | D | Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. | S1 p7-9 |
|  | 10c | V | For validation, describe how the predictions were calculated. | S1 p8-9 |
|  | 10d | D; V | Specify all measures used to assess model performance and, if relevant, to compare multiple models. | S1 p7-9 |
|  | 10e | V | Describe any model updating (e.g., recalibration) arising from the validation, if done. | S1 p9 |
| Risk groups | 11 | D;V | Provide details on how risk groups were created, if done. | S1 p9 |
| Development vs. validation | 12 | V | For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors. | NA |
| Results |  |  |  |  |
| Participants | 13a | D;V | Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful. | S1 p3-5,29 |
|  | 13b | D; V | Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome. | S1 p3-6 |
|  | 13c | V | For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome). | NA |
| Model development | 14a | D | Specify the number of participants and outcome events in each analysis. | S1 p18 |
|  | 14b | D | If done, report the unadjusted association between each candidate predictor and outcome. | NA |
| Model specification | 15a | D | Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point). | S1 p20 |
|  | 15b | D | Explain how to use the prediction model. | p19-20 |
| Model performance | 16 | D; V | Report performance measures (with Cls ) for the prediction model. | $\begin{gathered} \hline \text { S1 p24- } \\ 26,39 \end{gathered}$ |
| Model-updating | 17 | V | If done, report the results from any model updating (i.e., model specification, model performance). | NA |
| Discussion |  |  |  |  |
| Limitations | 18 | D; V | Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data). | p20 |
| Interpretation | 19a | V | For validation, discuss the results with reference to performance in the development data, and any other validation data. | NA |
|  | 19b | D; V | Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence. | p16-21 |
| Implications | 20 | D;V | Discuss the potential clinical use of the model and implications for future research. | p20-21 |


| Other information |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
| Supplementary <br> information | 21 | D;V | Provide information about the availability of supplementary resources, such as study protocol, <br> Web calculator, and data sets. | S1 p3 |
| Funding | 22 | D;V | Give the source of funding and the role of the funders for the present study. | p21-22 |

This study is a development and internal validation study under TRIPOD guidelines ${ }^{36}$
*Items relevant to model development are denoted by D , items relating to model validation are denoted by V

Figure 1: Flowchart of selection of study population, before population stratification


Figure 2: Flowchart of the classification process for UK Biobank medication names


[^1]Figure 3: Biomarker-age trends for the 72 candidate biomarkers, healthy men vs healthy women




\[

\]









Pulse rate

1200010:1:

: : : : ロ: ロ:: : :







|  | 1 | 1 | 1 | 1 |
| :---: | :---: | :---: | :---: | :---: |
| 40 |  |  |  |  |
| 45 | 50        <br> Baseline age        <br>      60 65 70 <br> Mean reticulocyte volume        |  |  |  |





- Healthy men
- Healthy women



Figure 4: Assessment of the need for stratification of healthy never vs healthy ex smokers: biomarker-age trends for the lung function biomarkers and systolic blood pressure, by sex


Key:

- Healthy never smokers
- Healthy ex smokers

Figure 5: Characterisation of 14 of the first 51 biomarker principal components


PC17 (eigenvalue: 1.19)


PC25 (eigenvalue: 0.93)


PC30 (eigenvalue: 0.84)


PC33 (eigenvalue: 0.78)


PC34 (eigenvalue: 0.76)


PC35 (eigenvalue: 0.73)


$$
\begin{aligned}
& \text { Red blood celk distrod cuition count } \\
& \text { Midth } \\
& \text { Mean corpuscular haemoglobin concente woutrotion }
\end{aligned}
$$




Rotated factor loading

PC47 (eigenvalue: 0.46)
PC48 (eigenvalue: 0.45)


Figure 6: 10-fold cross validation prediction errors (with standard error bars) for each subset of principal components (to a maximum of 55) using (A) Klemera Doubal age (top) and (B) stepwise regression age (bottom), for healthy men (left) and women (right)

## (A) Klemera Doubal age


(B) Stepwise regression age


These plots display prediction errors (mean square errors of biological ages; y-axes) and their standard error bars, for each biological age constructed from the specified number of principal components (x-axes). They were used to search for an elbow point, where beyond the elbow point there were diminishing changes in prediction error by increasing number of principal components.

Figure 7: Means and standard deviations of (A) Klemera Doubal (top) and (B) stepwise regression (bottom) biological ages by 2.5-year chronological age groups, for healthy men (left) and healthy women (right)

## (A) Klemera Doubal ages


(B) Stepwise regression ages


These plots indicate how well biological ages (y-axes) are calibrated to chronological age ( $x$-axes), and the variability (indicated by $\pm 1$ standard deviation bars) of individuals' biological ages in each 2.5-year chronological age group.

Figure 8: Kaplan-Meier plots for (1) mortality from chronic disease, (2) age-related hospital admissions and (3) CHD event or death, of the differences between chronological age and (A) Klemera Doubal or (B) stepwise regression biological ages, for healthy men (left) and healthy women (right)
(1) Mortality from chronic disease
(A) Klemera Doubal ages

(B) Stepwise regression ages


Predicted risk group Kaplan-Meier curve and 95\% confidence interval (shaded area):

$$
\begin{array}{ll}
\perp \mathrm{BA}-\mathrm{CA}<-5 \text { years } & \mathrm{BA}-\mathrm{CA}>5 \text { years } \\
\text { (Biologically younger) } & \\
\text { (Biologically older) }
\end{array}
$$

BA: biological age, CA: chronological age
Time is measured in years from baseline assessment
(2) CHD event or death

## (A) Klemera Doubal ages


(B) Stepwise regression ages


Predicted risk group Kaplan-Meier curve and 95\% confidence interval (shaded area):

$$
\begin{array}{ll}
\mathrm{BA}-\mathrm{CA}<-5 \text { years } & \mathrm{BA}-\mathrm{CA}>5 \text { years } \\
\text { (Biologically younger) } & \text { (Biologically older) }
\end{array}
$$

BA: biological age, CA: chronological age
Time is measured in years from baseline assessment

## (3) Age-related hospital admissions



Predicted risk group Kaplan-Meier curve and 95\% confidence interval (shaded area):
$+B A-C A<-5$ years
(Biologically younger)
$+|B A-C A|<5$ years
$\perp B A-C A>5$ years
(Biologically older)

BA: biological age, CA: chronological age
Time is measured in years from baseline assessment

## References

1. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLoS Med 2015; 12(3): e1001779.
2. UK Biobank. UK Biobank. http://www.ukbiobank.ac.uk/ (accessed 1 August 2019).
3. NHS Business Services Authority. BNF Code Information. 2017. https://www.nhsbsa.nhs.uk/
(accessed 6 December 2017).
4. Brilleman SL, Salisbury C. Comparing measures of multimorbidity to predict outcomes in primary care: a cross sectional study. Fam Pract 2013; 30(2): 172-8.
5. Tran J, Norton R, Conrad N, et al. Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: A population-based cohort study. PLoS Med 2018; 15(3): e1002513.
6. Kang YG, Suh E, Lee JW, Kim DW, Cho KH, Bae CY. Biological age as a health index for mortality and major age-related disease incidence in Koreans: National Health Insurance Service - Health screening 11year follow-up study. Clin Interv Aging 2018; 13: 429-36.
7. Gupta RP, Strachan DP. Ventilatory function as a predictor of mortality in lifelong non-smokers: evidence from large British cohort studies. BMJ Open 2017; 7(7): e015381.
8. Nakamura E, Miyao K. A method for identifying biomarkers of aging and constructing an index of biological age in humans. J Gerontol A Biol Sci Med Sci 2007; 62(10): 1096-105.
9. Jia L, Zhang W, Chen X. Common methods of biological age estimation. Clin Interv Aging 2017; 12: 759-72.
10. UK Biobank. Companion Document to Accompany Serum Biomarker Data. 2019.
http://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/serum_biochemistry.pdf (accessed 22 July 2019).
11. Yoo J, Kim Y, Cho ER, Jee SH. Biological age as a useful index to predict seventeen-year survival and mortality in Koreans. BMC Geriatr 2017; 17(1): 7.
12. Mamoshina P, Kochetov K, Putin E, et al. Population specific biomarkers of human aging: a big data study using South Korean, Canadian and Eastern European patient populations. J Gerontol A Biol Sci Med Sci 2018.
13. Levine ME. Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age? J Gerontol A Biol Sci Med Sci 2013; 68(6): 667-74.
14. Levine ME, Crimmins EM. A comparison of methods for assessing mortality risk. Am J Hum Biol 2014; 26(6): 768-76.
15. Jee H, Park J. Selection of an optimal set of biomarkers and comparative analyses of biological age estimation models in Korean females. Arch Gerontol Geriatr 2017; 70: 84-91.
16. Mitnitski A, Howlett SE, Rockwood K. Heterogeneity of Human Aging and Its Assessment. J Gerontol A Biol Sci Med Sci 2017; 72(7): 877-84.
17. Gilbert T, Neuburger J, Kraindler J, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet 2018; 391(10132): 1775-82.
18. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493737 UK Biobank participants. The Lancet Public Health 2018; 3(7): e323-e32.
19. Vetrano DL, Palmer K, Marengoni A, et al. Frailty and Multimorbidity: A Systematic Review and Meta-analysis. J Gerontol A Biol Sci Med Sci 2019; 74(5): 659-66.
20. Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet 2019; 394(10206): 1365-75.
21. Shrine N, Guyatt AL, Erzurumluoglu AM, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nat Genet 2019; 51(3): 481-93.
22. Zhang W, Jia L, Cai G, et al. Model Construction for Biological Age Based on a Cross-Sectional Study of a Healthy Chinese Han population. Journal of Nutrition, Health \& Aging 2017; 21(10): 1233-9.
23. Belsky DW, Caspi A, Houts R, et al. Quantification of biological aging in young adults. Proc Natl Acad Sci U S A 2015; 112(30): E4104-10.
24. Nakamura E, Miyao K, Ozeki T. Assessment of biological age by principal component analysis. Mech Ageing Dev 1988; 46(1-3): 1-18.
25. Cho IH, Park KS, Lim CJ. An empirical comparative study on biological age estimation algorithms with an application of Work Ability Index (WAI). Mech Ageing Dev 2010; 131(2): 69-78.
26. Zhong X, Lu Y, Gao Q, et al. Estimating Biological Age in the Singapore Longitudinal Aging Study. The Journals of Gerontology: Series A, Biological sciences and medical sciences 2019.
27. Klemera P, Doubal S. A new approach to the concept and computation of biological age. Mech Ageing Dev 2006; 127(3): 240-8.
28. Cohen AA, Milot E, Li Q, et al. Detection of a novel, integrative aging process suggests complex physiological integration. PLoS One 2015; 10(3): e0116489.
29. Ganna A, Ingelsson E. 5 year mortality predictors in 498,103 UK Biobank participants: a prospective population-based study. Lancet 2015; 386(9993): 533-40.
30. Liu Z, Kuo P-L, Horvath S, Crimmins E, Ferrucci L, Levine M. A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study. PLoS Med 2018; 15(12): e1002718.
31. Genizi A. Decomposition of $\mathrm{R}^{2}$ in multiple regression with correlated regressors. Statistica Sinica 1993; 3(2): 407-20.
32. Groemping U. Relative Importance for Linear Regression in R: The Package relaimpo. J Stat Soft 2006; 17(1): 27.
33. Grömping U. Variable importance in regression models. Wiley Interdisciplinary Reviews: Computational Statistics 2015; 7(2): 137-52.
34. Therneau T. A Package for Survival Analysis in S. Version 2.38. 2015. https://CRAN.Rproject.org/package=survival. (Accessed 5 November 2019)
35. Nagelkerke NJD. A note on a general definition of the coefficient of determination. Biometrika 1991; 78(3): 691-2.
36. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD StatementThe TRIPOD Statement. Ann Intern Med 2015; 162(1): 55-63.

[^0]:    CA: chronological age, BA: biological age

[^1]:    $\wedge$ Classification in this step was reviewed by a clinician

